International PhD Course in Molecular Medicine
PhD Supervisors
In this context, the role of the supervisor refers to a key figure involved in overseeing and guiding PhD students within the Research Laboratories at UniSR and OSR. The supervisor plays a crucial role in supporting the academic and professional development of doctoral candidates by providing guidance, advice, and mentoring throughout the research journey.
The responsibilities of the supervisor are diverse and encompass not only supporting research through specialized skills and knowledge in the field of study, which contribute to directing and consolidating the research project of the doctoral candidates, but also academic guidance activities. These activities assist the doctoral candidates in defining their research path, identifying meaningful thesis topics, and developing a coherent work plan.
Overall, the supervisor plays a crucial role in shaping the academic and professional trajectory of doctoral candidates by providing the necessary support for their success in both their studies and future careers.
Research Activity
Prof. Piero Barboni has been involved in clinical and translational research in ophthalmology, with a particular focus on neuro-ophthalmology and optic nerve disorders. Since 1988, he has dedicated a major part of his scientific activity to the study of hereditary optic neuropathies, especially Leber Hereditary Optic Neuropathy (LHON), and has collaborated with several international universities and research centers, including the University of Bologna, UCLA, the University of São Paulo, and the University of Cambridge.
His research activity also includes participation in international collaborative projects and working groups, such as the Concerted Action of the European Communities “Prevention of blindness: molecular research and medical care in retinitis pigmentosa” (1990–1993), The International Research Project on Leber Hereditary Optic Neuropathy in Brazil (2005–2011), and the Mitochondrial Disease Working Group of the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element Project (2021).
He has extensive experience in clinical studies and trials in the field of optic neuropathies, serving as Sub-Investigator in interventional studies initiated in 2018, 2020, and 2022, and as Principal Investigator in a clinical study started in 2023. His scientific output includes more than 170 peer-reviewed publications in international journals, as well as books and book chapters in the fields of neuro-ophthalmology, optic nerve imaging, mitochondrial medicine, and ophthalmic genetics.
Curriculum vitae
Name: Piero Barboni
ORCID: 0000-0002-0118-4177
H-index: 58
Nationality: Italian
Date of birth: January 8, 1960
Education
Degree in Medicine and Surgery, cum laude, University of Bologna, October 30, 1986.
Specialization in Ophthalmology, cum laude, University of Bologna, October 8, 1990.
Qualified for the position of Associate Professor (second-level academic qualification), 2021.
Professional experience
Private practice ophthalmologist from 1990 to the present.
Consultant neuro-ophthalmologist at IRCCS San Raffaele Hospital, Milan, from 2012 to the present.
Faculty member at the School of Specialization in Ophthalmology, San Raffaele Hospital, Milan.
Contract Professor at the Department of Neurological Sciences, University of Bologna, from 2007 to 2011.
Consultant neuro-ophthalmologist at Bellaria Hospital, Bologna, from 2016 to 2019.
Since 1990, his clinical practice has included refractive, cataract, glaucoma, and vitreoretinal surgery.
He also completed advanced training periods abroad at the Doheny Eye Institute, UCLA, Los Angeles, USA; the Wilmer Eye Institute, Baltimore, USA; and Bascom Palmer Eye Institute, University of Miami, USA.
Grants
/
Publications
Author of more than 170 peer-reviewed publications in international journals.
Editor of the following books:
OCT in CNS Diseases, 1st edition (2016), 2nd edition (2019), 3rd edition (2024).
LHON Atlas (2019).
Author of book chapters in:
Mitochondrial Medicine, Di Mauro, Informa, 1998, chapter: “Mitochondrial Ophthalmology”.
Oftalmologia Pediatrica e Strabismo, Nucci, Fabiano, 2012, chapter: “Otticopatie ereditarie in età pediatrica”.
Yanoff & Duker Ophthalmology, 4th edition (2014), 5th edition (2018), 6th edition (2022), chapter: “Imaging in Neuro-ophthalmology”.
Clinical Ophthalmic Genetics and Genomics, Elsevier, 2022, chapter: “Genetic Disorders Affecting the Optic Nerve”.
Leber Hereditary Optic Neuropathy, UNI-MED Verlag AG, 2024, chapter: “Phenotype of LHON”.
SIPE Guidelines, 2022 edition.
Professional Memberships and Scientific Roles
Member of the Board of:
European Neuro-Ophthalmology Society (EUNOS).
Società Italiana di Perimetria e Imaging (SIPE).
Member of:
European Association for Vision and Eye Research (EVER).
North American Neuro-Ophthalmology Society (NANOS).
Associazione Italiana di Cataratta e Refrattiva (AICCER).
Associazione Italiana di Scienze Oftalmologiche (SISO).
Handling Editor for Frontiers in Neurology and European Journal of Ophthalmology.
Founder of Studio Oculistico d’Azeglio with Dr. Giacomo Savini in 2008.
Organizer of the second-level Master’s program “Il nervo ottico” at Vita-Salute San Raffaele University, Milan, 1st edition in 2023 and 2nd edition in 2024.
Founder and organizer of the “Update on Optic Nerve Degeneration” international meeting, Milan 2016, from which the European Optic Nerve Network and the EUPON meetings originated.
Founder and organizer of the congress “La Neuro-oftalmologia alla portata di tutti”, now in its fifth edition.
Languages
Italian, English.
Research Activity
Raniero Chimienti’s research program lies at the intersection of stem cell engineering, transplantation immunology, and rare monogenic disease biology, with the overarching goal of developing safer and more effective cell-based therapies for diabetes. A major line of his work focuses on the generation of hypoimmunogenic stem cell-derived beta cells designed to remain functionally competent while becoming less visible to the host immune system. This activity combines gene editing, in vitro differentiation, and transplantation studies in humanized models to define strategies that may reduce or avoid rejection of cell therapy products for type 1 diabetes.
A second major research line investigates the contribution of Killer-cell Immunoglobulin-like Receptors (KIRs), HLA ligands, and the innate immune system to rejection risk in solid organ and islet transplantation. In this area, his work integrates immunogenetics, functional assays, and translational modeling to understand how donor-recipient KIR/HLA combinations shape immune activation and transplant outcome. This effort also supports the development of next-generation tools for high-throughput KIR genotyping and for the identification of immunogenetic profiles associated with favorable or unfavorable transplant outcomes.
A third research focus addresses the genetics and etiopathogenesis of Wolfram syndrome, with particular attention to the consequences of WFS1 mutations on beta-cell biology and to the role of inflammation and immune dysregulation in disease progression. Through patient-derived models, molecular studies, and immune phenotyping, his research aims to dissect the crosstalk between immune cells and beta cells, clarify genotype-phenotype relationships, and identify disease mechanisms that may inform future therapeutic strategies. Across these lines of work, his research is characterized by a strong translational orientation, bridging mechanistic biology with clinically relevant questions in diabetes, transplantation, and monogenic disease.
Curriculum vitae
Education
01/2014 – 04/2017 PhD in Experimental Medicine and Medical Biotechnologies, University of Milan, Department of Medical Biotechnology and Translational Medicine, Milan, Italy. Dissertation: “Functional relevance of D4Z4-derived antisense and coding sense transcripts on dysregulation of myogenesis in facioscapulohumeral muscular dystrophy”.
11/2011 – 10/2013 Master’s Degree in Medical Biotechnology, University of Milano-Bicocca, Department of Medicine and Surgery, Milan, Italy.
09/2007 – 11/2011 Bachelor’s Degree in Biotechnology, University of Milano-Bicocca, Department of Medicine and Surgery, Milan, Italy.
Professional experience
11/2025 – present Adjunct Professor for the course “Stem Cells, Organoids and Tissue Engineering: the Foundations of Regenerative Medicine”, International MD Program, Vita-Salute San Raffaele University, Milan, Italy.
01/2025 – present Principal Investigator, Beta Cell Biology Unit, Diabetes Research Institute (DRI), Vita-Salute San Raffaele University, Milan, Italy.
12/2022 – 12/2024 Research Investigator, Beta Cell Biology Unit, IRCCS San Raffaele Scientific Institute, Diabetes Research Institute (DRI), Milan, Italy.
11/2021 – 11/2022 Postdoctoral Researcher, Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Disease (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy.
04/2017 – 10/2021 Postdoctoral Researcher, Beta Cell Biology Unit, IRCCS San Raffaele Scientific Institute, Diabetes Research Institute (DRI), Milan, Italy.
10/2013 – 12/2013 Research Fellow, Functional and Structural Genomics Unit, International School for Advanced Studies (SISSA), Department of Neuroscience, Trieste, Italy.
Grants
2027 – 2029. Breakthrough T1D Strategic Research Agreement (SRA) – Principal Investigator. Project: “Immunosurveillance of Viral Infections in Hypoimmunogenic SC-Islet Therapy for Type 1 Diabetes”. Grant No.: 2-SRA-2026-1930-S-B; Funding: $519,258; Duration: 2 years.
2026 – 2027. Fondazione Silvio Tronchetti-Provera Donation – Principal Investigator. Project: “Gene therapy approach for restoring WFS1 function in hematopoietic stem cell precursors from Wolfram patients”. Funding: $23,563; Duration: 1 year.
2025 – 2026. Fondazione Silvio Tronchetti-Provera & The Snow Foundation Joint Donation – Principal Investigator. Project: “Gene therapy approach for restoring WFS1 function in hematopoietic stem cell precursors from Wolfram patients”. Funding: $39,858; Duration: 1 year.
2025 – 2027. Fondazione Telethon Multi-Round Call 21/24 (Round 4) – Principal Investigator. Project: “Impact of WFS1-related mutations on immune system dysregulation in Wolfram Syndrome 1”. Grant No.: GMR24T1147; Funding: $167,661; Duration: 2 years.
2024 – 2027. Breakthrough T1D Strategic Research Agreement (SRA) – Co-Principal Investigator (PI: Prof. Lorenzo Piemonti; co-PI: Dr. Valeria Sordi). Project: “Late pre-clinical validation of safety and long-term functionality of hypoimmunogenic iPSC-derived β cells into fully humanized transgenic mouse model of Type 1 Diabetes”. Grant No.: 3-SRA-2024-1528-S-B; Funding: $999,996; Duration: 3 years.
2022 – 2026. Breakthrough T1D Strategic Research Agreement (SRA) – Co-Principal Investigator (PI: Prof. Lorenzo Piemonti; co-PI: Dr. Mauro Malnati). Project: “Impact of NK cells on the outcome of transplantation in patients with Type 1 Diabetes”. Grant No.: 3-SRA-2022-1254-S-B; Funding: $699,918; Duration: 4 years.
2025 – 2028. Breakthrough T1D FY24 RFA: Development of Interventions to Modulate Immune Cell Trafficking in T1D (SRA) – Key personnel [effort 5%] (PI: Prof. Lorenzo Piemonti; co-PI: Dr. Andrea Laurenzi). Project: “Ladarixin and Antithymocyte Globulin (ATG) in New Onset Type 1 Diabetes”. Grant No.: 3-SRA-2025-1622-M-B; Funding: $999,996; Duration: 3 years.
2021 – 2022. EFSD/JDRF/Lilly European Programme in Type 1 Diabetes Research Grant – Co-Principal Investigator (PI: Prof. Lorenzo Piemonti). Project: “Exploitation of the immune checkpoints B7-H3 and CD155 to enhance engraftment of hiPSC-derived β cells”. Funding: $98,625; Duration: 1 year.
Publications
Siracusano G, Deambrogio F, Sordi V, Malnati M, Piemonti L*, Chimienti R*. Blockade of CD155 and CD276 by monoclonal antibodies fosters immune tolerance and promotes stable engraftment of iPSC-derived islets in allogeneic humanized mice. Transpl Int. 2025 Dec 1;38:15433. doi: 10.3389/ti.2025.15433. *co-last authors.
Torchio S†, Siracusano G†, ..., Sordi V, Chimienti R*, Piemonti L*. Liraglutide treatment reverses unconventional cellular defects in induced pluripotent stem cell-derived β cells harboring a partially functional WFS1 variant. Diabetes. 2025 Jul 1;74(7):1273-1288. doi: 10.2337/db24-0720. †contributed equally; *co-last authors.
Bechi Genzano C, Young T, Bonami R, Chimienti R, …, Creusot RJ. Autoimmune diabetes and targets for immunomodulation. Semin Immunol. 2025;79:101983. doi: 10.1016/j.smim.2025.101983.
Caretto A, Scarascia Mugnozza F, Valsecchi F, Pedone E, Pozzoni M, Rosa S, Laurenzi A, Frontino G, Chimienti R, Piemonti L, Scavini M. Diabetes mellitus and pregnancy in Wolfram syndrome type 1: a case report with review of clinical and pathophysiological aspects. Front Med (Lausanne). 2025 Sep 8;12:1639884. doi: 10.3389/fmed.2025.1639884.
Chimienti R, Siracusano G, Melzi R, …, Caldara R, Biassoni R, Malnati M, Piemonti L. Harnessing KIR/HLA (mis)matching to predict pancreatic islet transplant outcomes. Transplantation. 2025 Jun;109(6S1):67–68. doi: 10.1097/01.tp.0001123320.62156.ff.
Siracusano G*, Chimienti R*, Tacconi C, …, Sordi V, Malnati M, De Giovanni M, Piemonti L. Breaking immune evasion: NK cell surveillance of hypoimmunogenic iPSC-derived pancreatic islets during viral infections. Transplantation. 2025 Jun;109(6S1):8. doi: 10.1097/01.tp.0001122904.85848.1f. *contributed equally.
Siracusano G*, Chimienti R*, Tacconi C, …, Sordi V, Malnati M, De Giovanni M, Piemonti L. The immunosurveillance of hypoimmunogenic iPSC-derived pancreatic islets: impact of viral infections. Cytotherapy. 2025;27(5 Suppl):S46. doi: 10.1016/j.jcyt.2025.03.074. *contributed equally.
Chimienti R*, Torchio S*, Siracusano G, Zamarian V, Monaco L, Lombardo MT, …, Broccoli V, Bonfanti R, Casari G, Frontino G, Piemonti L. A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on β cell apoptosis in a patient with Wolfram syndrome. Diabetologia. 2025 Jan;68(1):128-151. doi: 10.1007/s00125-024-06307-0. *contributed equally.
Noviello M*, De Lorenzo R*, Chimienti R, Maugeri N, …, Rovere-Querini P, Bonini C. The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients’ survival and long COVID. Front Immunol. 2024;15:1381091. doi: 10.3389/fimmu.2024.1381091. *contributed equally.
Chimienti R, Siracusano G, …, Malnati M, Piemonti L. Knock-out of the NK activating ligands in MHC-I-null human stem cell-derived β cells avoids chronic allogeneic rejection and reverts hyperglycemia in diabetic humanized mice. Cytotherapy. 2024;26(6):S15. doi: 10.1016/j.jcyt.2024.03.026.
Caldara R*, Tomajer V*, Monti P*, Sordi V*, Citro A*, Chimienti R, Gremizzi C, Catarinella D, Tentori S, Paloschi V, …, Nano R, Magistretti P, Partelli S, Piemonti L. Allo beta cell transplantation: specific features, unanswered questions, and immunological challenge. Front Immunol. 2023 Nov 23;14:1323439. doi: 10.3389/fimmu.2023.1323439. *contributed equally.
Chimienti R*, Baccega T*, Torchio S, Menenti F, Pellegrini S, Cospito A, Amabile A, Lombardo MT, Monti P, Sordi V, Lombardo A, Malnati M, Piemonti L. Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for β cell replacement. Cell Reports. 2022 Sep 27;40(13):111423. doi: 10.1016/j.celrep.2022.111423. *contributed equally.
Frontino G, Raouf T, Canarutto D, Tirelli E, Di Tonno R, Rigamonti A, …, Barera G, Broccoli V, Rossi G, Torchio S, Chimienti R, Bonfanti R, Piemonti L. Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients. Front Pediatr. 2021 Dec 14;9:755365. doi: 10.3389/fped.2021.755365.
Pellegrini S*, Chimienti R*, Scotti GM, ..., Nano R, Piemonti L, Sordi V. Transcriptional dynamics of induced pluripotent stem cell differentiation into β cells reveals full endodermal commitment and homology with human islets. Cytotherapy. 2021;23(4):311-319. doi: 10.1016/j.jcyt.2020.10.004. *contributed equally.
Chimienti R, Baccega T, Manenti F, Torchio S, ..., Malnati M, Piemonti L. Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I−/− iPSC-derived β cells for cell therapy of type 1 diabetes. Cytotherapy. 2020;22(5):S15. doi: 10.1016/j.jcyt.2020.03.479.
Dugnani E, Sordi V, Pellegrini S, Chimienti R, Marzinotto I, …, Lampasona V, Piemonti L. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: a correlation with clinical outcome. Pancreatology. 2018;18(8):945-953. doi: 10.1016/j.pan.2018.09.006.
Pellegrini S, Manenti F, Chimienti R, Nano R, Ottoboni L, ..., Piemonti L, Sordi V. Differentiation of Sendai Virus-Reprogrammed iPSC into β Cells, Compared with Human Pancreatic Islets and Immortalized β Cell Line. Cell Transplantation. 2018;27(10):1548-1561. doi: 10.1177/09636897187985
Research Activity
The area of research is physics applied to medicine. Major activities concern Radiotherapy, predictive models in Oncology and Medical Imaging, including: outcome modelling, imaging biomarkers, radiomics, automation in Radiotherapy, AI-based auto-segmentation, AI/machine learning in predictive models for Oncology and Imaging, Digital Pathology, pre-clinical and clinical Radiobiology.
(PHYS-06/A - Fisica per le scienze della vita, l'ambiente e i beni culturali)
Curriculum vitae
Education
1990 Master degree (MSc) in Physics, Università Statale di Milano
1994 Specialization in Medical Physics, Università Statale di Milano
Professional experience
1990-1991 Research fellow at the Medical Physics Dept of San Raffaele Institute
Since 1991 Medical Physicist in the Medical Physics Dept of San Raffaele Institute
Since 2017 Teacher at the Specialization School of Medical Physics, Università Statale di Milano
Since 2019 Assistant Professor at the MD program Faculty, Università Vita Salute San Raffaele, Milano
Since 2023 Assistant Professor at the Medicina and Obstetric Faculties, Università Vita Salute San Raffaele, Milano
Since 2025 Assistant Professor at the Radiology Technicians Faculty, Università Vita Salute San Raffaele, Milano
Summary of other relevant Scientific and Editorial activities:
Member of the ESTRO Physics Committee (2007-2020) and past member of the ESTRO Board (2017-2019); Member of the steering board of EORTC-ESTRO E2Radiate task group and of the QUANTEC_2 AAPM/ASTRO/ESTRO initiative. Co-coordinator of the AIFM Research Commission (2021-2025).
Member of the scientific committee of numerous national and international congresses and conferences. Among the most important: ESTRO, European Society of Therapeutic Radiation Oncology (from 2002 to 2019) and Co_chair of the ESTRO congress 2016 (Vienna) . ICCR, International Conference on the use of the Computer in Radiotherapy (2019, 2024, 2027); AIFM, Associazione Italiana di Fisica Medica (2023)
Member of the Editorial Board of: Physica Medica (since 2002), Radiother & Oncol (since 2003), Radiation Oncology (since 2007), Phiro (2015-2024). Associate Editor of Cancers (since 2020) and Frontiers in Oncology (since 2019); Past Associate Senior Editor of Int J Radiat Oncol Biol Phys (2012-2014) and Physica Medica (2014-2020); current Deputy Editor of Physica Medica (since 2021)
National Scientific Qualification, 27/11/2013-31/12/2025, in 02/D1, scientific-disciplinary sector FIS07 (Associate Professor, second band).
National Scientific Qualification, 11/11/2025-11/11/2037, in the field 02/D1, scientific-disciplinary sector FIS06 (Associate Professor, second level)
Grants
As Leader/co-leader
PI project AIRC 8748: Predictive models of genito-urinary and sexual dysfunctions after high dose RT for prostate cancer (Jan 2010-Dec 2012):
PI project AIRC IG13090: GU and sexual dysfunction after high-dose RT for prostate cancer: finding dose-volume and clinical predictors (Jan 2013-Dec 2015
PI project AIRC IG18965: Increasing the reliability of FDG-PET radiomic features to predict theresponse to Radiotherapy (Jan 2017 - Dec 2019)
PI project AIRC IG23150: Mikapoco (Jan 2020 - Dec 2025): WP leader of the project ERAPERMED: PerPlanRT (Jun 2021 - Dec 2024)
co-PI (now PI) of the poroject “Ricerca Finalizzata”: Federated Learning as a step forward in digital pathology-AI-Flopp”(Mar 2023-May 2027):
PI of the project “PNRR”: Developing and optimizing X-Rays mini-beam Radiotherapy (May 2023-May 2026):
WP leader of the project EURATOM: "TETRIS - risk assessment tools for severe Side effects after breast radiotherapy: Radiation safety through biological extended models and digital twins" (Oct 2024 - oct 2027)
PI project AIRC IG 2025 ID 32254: Reducing toxicity after breast cancer Radiotherapy through predictive models and care personalization (Jan 2026 – ongoing)
As collaborator
AIRC project: "Simultaneous integrated boost for concomitant treating pelvic nodes and prostate with moderate hypofractionation" (PI: Dr Valdagni, 2008-2010).
AIRC project: "Modelling of salivary function in head and neck cancer IMRT by means of deformable registration tools (PI: GM Cattaneo, 2010-2012)
AIRC project: "Longitudinal evaluation of intestinal and haematologic toxicity from pelvic irradiation for prostate cancer" (PI: Dr Cozzarini, 2014-2016)
AIRC project "Modelling toxicity after high dose RT for prostate cancer: validating clinical, dosimetric and molecular factors" (PI: R Valdagni, 2015-2017)
AIRC project IG 2018 - ID. 21441 "Pre-clinical assessment of protective role of antiandrogens in reducing urinary toxicity after high-dose radiotherapy" (PI: Dr Cozzarini, 2018-2023)
AIRC project IG23015 "Prediction of response to neo-adjuvant Chemo-Radio-Therapy (nCRT) for esophageal cancer using a fully integrated PET/MRI" (PI: Prof De Cobelli, 2020-2024)
AIRC project: "Mechanistic insights in preclinical FLASH radiotherapy through advanced dosimetry and biophysical modeling" (PI A Spinelli, 2023-2027)
AIRC project: "Toward clinical use of PET in selecting patients with pancreatic cancer for local treatment intensification" (PI: Prof Di Muzio, 2023-2028)
Project of CCM - Ministero della Salute "Segmentazione del CTV basato su IA nella Radioterapia della mammella: esplorazione di modelli utilizzabili su larga scala, incluso mappe di probabilità intra- ed inter-Centro" (PI, A Palma, ISS, 2025-2027)
Publications
309 publications (Source Scopus, april 2026), h-index: 51, total number of citations 8800
ORCID: https://orcid.org/0000-0002-0013-8494
RESEARCHER ID J-8650-2018
Google Scholar - https://scholar.google.com/citations?user=o1NehskAAAAJ&hl=ittale
Complete list of the period 2002-2026 (PubMed export):
1: Di Muzio N, Torrisi M, Barzaghi R, Pocaterra A, Mori M, Folchini F, Giannini
L, Valle M, Bailo M, Deantoni CL, Snider S, Gagliardi F, Ruggiero E, Broggi S,
Ruffino L, Di Franco R, Mercogliano S, Fiorino C, Del Vecchio A, Muto M, Muto P,
Mortini P, Mondino A, Fodor A. Neoadjuvant ultrahypofractionated radiotherapy
with simultaneous integrated boost for glioblastoma: study protocol for a phase
I multicenter clinical trial. BMC Cancer. 2026 Apr 6. doi:
10.1186/s12885-026-15950-2. Epub ahead of print. PMID: 41942944.
2: Kolias P, Ajdari A, Cicchetti A, Jeraj R, Toma-Dasu I, Thorwarth D, Gani C,
Thieke C, Nicolay NH, Fiorino C, Bortfeld T, Niyazi M. Integrating biomarker-
derived individual treatment response assessment into Bayesian trial design for
personalized cancer treatment. Radiother Oncol. 2026 Mar 12;219:111484. doi:
10.1016/j.radonc.2026.111484. Epub ahead of print. PMID: 41831619.
3: Carconi C, Capurso G, Abati M, Vincenzi MM, Burini A, Cardellini S, Pavarini
M, Ubeira-Gabellini MG, Palumbo D, Pecorelli N, Macchini M, Liscia N, Campisi A,
Guarneri G, Vanella G, Fiorino C, Falconi M, Reni M, Orsi G. Pancreatic
adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in
advanced pancreatic cancer. Dig Liver Dis. 2026 Mar 6:S1590-8658(26)00293-8.
doi: 10.1016/j.dld.2026.02.015. Epub ahead of print. PMID: 41794561.
4: Mori M, Belardo A, Vincenzi MM, Fodor A, Mangili P, Palazzo G, Gabellini MGU,
Tummineri R, Torrisi M, Vecchio AD, Muzio NGD, Fiorino C. Breast Density
Histogram Analysis: The Role of Fat in Outcome Prediction After Whole Breast
Radiation Therapy. Pract Radiat Oncol. 2025 Dec 13:S1879-8500(25)00319-4. doi:
10.1016/j.prro.2025.12.004. Epub ahead of print. PMID: 41397616.
5: Cicchetti A, Mori M, Passoni P, Broggi S, Reni M, De Cobelli F, Rosati R,
Placidi L, Romano A, Chiloiro G, Boldrini L, Gambacorta MA, Del Vecchio A, Di
Muzio NG, Fiorino C. Incorporating Individual Early Response in the Dose-Effect
Relationship of Complete Pathological Response Following Neoadjuvant
Radiochemotherapy for Rectal Cancer. Int J Radiat Oncol Biol Phys. 2025 Dec
5:S0360-3016(25)06543-5. doi: 10.1016/j.ijrobp.2025.11.059. Epub ahead of print.
PMID: 41354181.
6: Placidi L, Griffin P, Castriconi R, Tudda A, Benecchi G, Burns M, Cagni E,
Markham C, Landoni V, Moretti E, Oliviero C, Guidasci GR, Meffe G, Rancati T,
Scaggion A, McGoldrick K, Panettieri V, Fiorino C. An International Inter-
Consortium Validation of Knowledge-Based Plan Prediction Modeling for Whole
Breast Radiotherapy Treatment. Cancers (Basel). 2025 Nov 5;17(21):3576. doi:
10.3390/cancers17213576. PMID: 41228368; PMCID: PMC12610825.
7: Fodor A, Giannini L, Torrisi M, Brombin C, Broggi S, Losa A, Maga T, Mellone
R, Martinenghi C, Tummineri R, Mangili P, Deantoni CL, Tudda A, Castriconi R,
Rancoita PMV, Di Serio MS, Gaboardi F, Fiorino C, Del Vecchio A, Chiti A, De
Cobelli F, Di Muzio N. Comprehensive one-day management of prostate cancer
patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic
SBRT. Radiat Oncol. 2025 Aug 27;20(1):134. doi: 10.1186/s13014-025-02713-9.
PMID: 40866948; PMCID: PMC12392665.
8: Pizzardi S, Alborghetti L, Vurro F, Lacavalla MA, Capialbi MM, Milani P,
Cavaliere F, Fiorino C, Spinelli AE. Development of a preclinical X-rays
minibeam Monte Carlo treatment planning system. Sci Rep. 2025 Aug
15;15(1):29926. doi: 10.1038/s41598-025-15281-5. PMID: 40817138; PMCID:
PMC12356841.
9: Belardo A, Dimayuga KB, Perna L, Fodor A, Giannini L, Mangili P, Palazzo G,
Pasetti M, Torrisi M, Tummineri R, Vecchio AD, Di Muzio NG, Fiorino C. Density
and volume of cardiac calcifications detected on planning CT predicts
cardiotoxicity after hypo-fractionated whole breast Radiotherapy. Radiother
Oncol. 2025 Oct;211:111098. doi: 10.1016/j.radonc.2025.111098. Epub 2025 Aug 10.
PMID: 40796017.
10: Fodor A, Midulla M, Brombin C, Rancoita PMV, Bergamini A, Mangili P, Torrisi
M, Perna L, Rabaiotti E, Dell'Oca I, Deantoni CL, Bocciolone L, Fiorino C, Del
Vecchio A, Di Serio MS, Mangili G, Di Muzio NG. 18F-FDG PET/CT guided salvage
radiotherapy strategies for lymph-nodal relapses in gynecological cancers: SBRT
vs ENRT. Tumori. 2025 Jun;111(3):219-228. doi: 10.1177/03008916251336055. Epub
2025 Apr 18. PMID: 40251799; PMCID: PMC12163193.
11: Ubeira-Gabellini MG, Palazzo G, Mori M, Tudda A, Rivetti L, Cagni E,
Castriconi R, Landoni V, Moretti E, Mazzilli A, Oliviero C, Placidi L, Guidasci
GR, Riani C, Fodor A, Muzio NGD, Jeraj R, Vecchio AD, Fiorino C. Development and
external multicentric validation of a deep learning-based clinical target volume
segmentation model for whole-breast radiotherapy. Phys Imaging Radiat Oncol.
2025 Mar 26;34:100749. doi: 10.1016/j.phro.2025.100749. PMID: 40242807; PMCID:
PMC12002654.
12: Vincenzi MM, Mori M, Passoni P, Tummineri R, Slim N, Midulla M, Palazzo G,
Belardo A, Spezi E, Picchio M, Reni M, Chiti A, Del Vecchio A, Fiorino C, Di
Muzio NG. Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-
Free-Survival After Radio-Chemotherapy for Pancreatic Adenocarcinoma. Cancers
(Basel). 2025 Mar 20;17(6):1036. doi: 10.3390/cancers17061036. PMID: 40149369;
PMCID: PMC11941493.
13: Tudda A, Castriconi R, Placidi L, Benecchi G, Buono RC, Cagni E, Cicchetti
A, Landoni V, Malatesta T, Mazzilli A, Meffe G, Moretti E, Mori M, Oliviero C,
Guidasci GR, Scaggion A, Trojani V, Vecchio AD, Fiorino C. Multi-institutional
Knowledge-Based (KB) plan prediction benchmark models for whole breast
irradiation. Phys Med. 2025 Feb;130:104889. doi: 10.1016/j.ejmp.2024.104889.
Epub 2025 Jan 16. PMID: 39823915.
14: Marson F, Pizzardi S, Alborghetti L, Vurro F, Lacavalla MA, Fiorino C,
Spinelli AE. Real-time dose measurement in minibeam radiotherapy using
radioluminescence imaging. Phys Med. 2025 Feb;130:104894. doi:
10.1016/j.ejmp.2025.104894. Epub 2025 Jan 11. PMID: 39799812.
15: Landoni V, Broggi S, Serra M, Doro R, Stefania Martinotti A, Redaelli I,
Cristina Frassanito M, Siragusa C, De Martin E, Soriani A, Tudda A, Castriconi
R, Del Vecchio A, Masi L, Fiorino C. Multicenter approach to predict plan
quality of robotic intracranial SRS/SRT. Phys Med. 2025 Jan;129:104887. doi:
10.1016/j.ejmp.2024.104887. Epub 2024 Dec 31. PMID: 39742827.
16: Vincenzi MM, Cicchetti A, Castriconi R, Mangili P, Ubeira-Gabellini MG,
Chiara A, Deantoni C, Mori M, Pasetti M, Palazzo G, Tummineri R, Rancati T, Di
Muzio NG, Vecchio AD, Fodor A, Fiorino C. Training and temporally validating an
NTCP model of acute toxicity after whole breast radiotherapy, including the
impact of advanced delivery techniques. Radiother Oncol. 2025 Mar;204:110700.
doi: 10.1016/j.radonc.2024.110700. Epub 2024 Dec 25. PMID: 39725068.
17: Deantoni CL, Fiorino C, Chiara A, Torrisi M, Giannini L, Loria A, Fodor A,
Broggi S, Pasetti M, Di Muzio N, Dell'Oca I. A Case of Radiotherapy During
Pregnancy for Oropharyngeal Cancer: Long-Term Pediatric Outcome Evaluation and
Literature Review. Pract Radiat Oncol. 2025 Mar-Apr;15(2):e95-e99. doi:
10.1016/j.prro.2024.06.018. Epub 2024 Aug 23. PMID: 39182646.
18: Koksal Akbas C, Vurro F, Fiorino C, Cozzarini C, Cavaliere F, Milani P,
Broggi S, Del Vecchio A, Di Muzio N, Tacchetti C, Enrico Spinelli A. Preclinical
photon minibeam radiotherapy using a custom collimator: Dosimetry
characterization and preliminary in-vivo results on a glioma model. Phys Med.
2024 Aug;124:103420. doi: 10.1016/j.ejmp.2024.103420. Epub 2024 Jul 5. PMID:
38970950.
19: Passoni P, Reni M, Broggi S, Slim N, Fodor A, Macchini M, Orsi G, Peretti U,
Balzano G, Tamburrino D, Belfiori G, Cascinu S, Falconi M, Fiorino C, Di Muzio
N. Hypofractionated radiotherapy concomitant to capecitabine after induction
chemotherapy for advanced pancreatic adenocarcinoma. Clin Transl Radiat Oncol.
2024 Apr 12;47:100778. doi: 10.1016/j.ctro.2024.100778. PMID: 38779525; PMCID:
PMC11108816.
20: Della Corte A, Mori M, Calabrese F, Palumbo D, Ratti F, Palazzo G,
Pellegrini A, Santangelo D, Ronzoni M, Spezi E, Del Vecchio A, Fiorino C,
Aldrighetti L, De Cobelli F. Preoperative MRI radiomic analysis for predicting
local tumor progression in colorectal liver metastases before microwave
ablation. Int J Hyperthermia. 2024;41(1):2349059. doi:
10.1080/02656736.2024.2349059. Epub 2024 May 16. PMID: 38754994.
21: Boldrini L, Chiloiro G, Cusumano D, Yadav P, Yu G, Romano A, Piras A, Votta
C, Placidi L, Broggi S, Catucci F, Lenkowicz J, Indovina L, Bassetti MF, Yang Y,
Fiorino C, Valentini V, Gambacorta MA. Radiomics-enhanced early regression index
for predicting treatment response in rectal cancer: a multi-institutional 0.35 T
MRI-guided radiotherapy study. Radiol Med. 2024 Apr;129(4):615-622. doi:
10.1007/s11547-024-01761-7. Epub 2024 Mar 21. PMID: 38512616.
22: Pavarini M, Alborghetti L, Aimonetto S, Maggio A, Landoni V, Ferrari P,
Bianculli A, Petrucci E, Cicchetti A, Farina B, Ubeira-Gabellini MG, Salmoiraghi
P, Moretti E, Avuzzi B, Giandini T, Munoz F, Magli A, Sanguineti G, Magdalena
Waskiewicz J, Rago L, Cante D, Girelli G, Vavassori V, Di Muzio NG, Rancati T,
Cozzarini C, Fiorino C. Pelvic bone marrow dose-volume predictors of late
lymphopenia following pelvic lymph node radiation therapy for prostate cancer.
Radiother Oncol. 2024 Jun;195:110230. doi: 10.1016/j.radonc.2024.110230. Epub
2024 Mar 17. PMID: 38503355.
23: Castriconi R, Tudda A, Placidi L, Benecchi G, Cagni E, Dusi F, Ianiro A,
Landoni V, Malatesta T, Mazzilli A, Meffe G, Oliviero C, Rambaldi Guidasci G,
Scaggion A, Trojani V, Del Vecchio A, Fiorino C. Inter-institutional variability
of knowledge-based plan prediction of left whole breast irradiation. Phys Med.
2024 Apr;120:103331. doi: 10.1016/j.ejmp.2024.103331. Epub 2024 Mar 13. PMID:
38484461.
24: Ubeira-Gabellini MG, Mori M, Palazzo G, Cicchetti A, Mangili P, Pavarini M,
Rancati T, Fodor A, Del Vecchio A, Di Muzio NG, Fiorino C. Comparing
Performances of Predictive Models of Toxicity after Radiotherapy for Breast
Cancer Using Different Machine Learning Approaches. Cancers (Basel). 2024 Feb
25;16(5):934. doi: 10.3390/cancers16050934. PMID: 38473296; PMCID: PMC10930533.
25: Cicchetti A, Mangili P, Fodor A, Gabellini MGU, Chiara A, Deantoni C, Mori
M, Pasetti M, Palazzo G, Rancati T, Del Vecchio A, Gisella Di Muzio N, Fiorino
C. Skin dose-volume predictors of moderate-severe late side effects after whole
breast radiotherapy. Radiother Oncol. 2024 May;194:110183. doi:
10.1016/j.radonc.2024.110183. Epub 2024 Feb 27. PMID: 38423138.
26: Maggio A, Rancati T, Gatti M, Cante D, Avuzzi B, Bianconi C, Badenchini F,
Farina B, Ferrari P, Giandini T, Girelli G, Landoni V, Magli A, Moretti E,
Petrucci E, Salmoiraghi P, Sanguineti G, Villa E, Waskiewicz JM, Guarneri A,
Valdagni R, Fiorino C, Cozzarini C. Quality of Life Longitudinal Evaluation in
Prostate Cancer Patients from Radiotherapy Start to 5 Years after IMRT-IGRT.
Curr Oncol. 2024 Feb 1;31(2):839-848. doi: 10.3390/curroncol31020062. PMID:
38392056; PMCID: PMC10887595.
27: Sanguineti G, Pavarini M, Munoz F, Magli A, Cante D, Garibaldi E, Gebbia A,
Noris Chiorda B, Girelli G, Villa E, Faiella A, Magdalena Waskiewicz J, Avuzzi
B, Pastorino A, Moretti E, Rago L, Statuto T, Gatti M, Rancati T, Valdagni R,
Luigi Vavassori V, Gisella Di Muzio N, Fiorino C, Cozzarini C. Worsening of
2-year patient-reported intestinal functionality after radiotherapy for prostate
cancer including pelvic node irradiation. Radiother Oncol. 2024 Mar;192:110088.
doi: 10.1016/j.radonc.2024.110088. Epub 2024 Jan 8. PMID: 38199284.
28: Deantoni CL, Mirabile A, Chiara A, Giannini L, Midulla M, Del Vecchio A,
Fiorino C, Fodor A, Di Muzio NG, Dell'Oca I. Impact of low skeletal muscle mass
in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A
mono-institutional experience. Tumori. 2024 Apr;110(2):116-123. doi:
10.1177/03008916231212382. Epub 2023 Nov 17. PMID: 37978342; PMCID: PMC11005313.
29: Palazzo G, Mangili P, Deantoni C, Fodor A, Broggi S, Castriconi R, Ubeira
Gabellini MG, Del Vecchio A, Di Muzio NG, Fiorino C. Real-world validation of
Artificial Intelligence-based Computed Tomography auto-contouring for prostate
cancer radiotherapy planning. Phys Imaging Radiat Oncol. 2023 Oct 13;28:100501.
doi: 10.1016/j.phro.2023.100501. PMID: 37920450; PMCID: PMC10618761.
30: Spampinato S, Rancati T, Waskiewicz JM, Avuzzi B, Garibaldi E, Faiella A,
Villa E, Magli A, Cante D, Girelli G, Gatti M, Noris Chiorda B, Rago L, Ferrari
P, Piva C, Pavarini M, Valdagni R, Vavassori V, Munoz F, Sanguineti G, Di Muzio
N, Kirchheiner K, Fiorino C, Cozzarini C. Patient-reported persistent symptoms
after radiotherapy and association with quality of life for prostate cancer
survivors. Acta Oncol. 2023 Nov;62(11):1440-1450. doi:
10.1080/0284186X.2023.2259597. Epub 2023 Nov 7. PMID: 37801288.
31: Alborghetti L, Castriconi R, Sosa Marrero C, Tudda A, Ubeira-Gabellini MG,
Broggi S, Pascau J, Cubero L, Cozzarini C, De Crevoisier R, Rancati T, Acosta O,
Fiorino C. Selective sparing of bladder and rectum sub-regions in radiotherapy
of prostate cancer combining knowledge-based automatic planning and
multicriteria optimization. Phys Imaging Radiat Oncol. 2023 Aug 28;28:100488.
doi: 10.1016/j.phro.2023.100488. PMID: 37694264; PMCID: PMC10482897.
32: Loi S, Mori M, Palumbo D, Crippa S, Palazzo G, Spezi E, Del Vecchio A,
Falconi M, De Cobelli F, Fiorino C. Limited impact of
discretization/interpolation parameters on the predictive power of CT radiomic
features in a surgical cohort of pancreatic cancer patients. Radiol Med. 2023
Jul;128(7):799-807. doi: 10.1007/s11547-023-01649-y. Epub 2023 Jun 8. PMID:
37289267.
33: Monticelli D, Castriconi R, Tudda A, Fodor A, Deantoni C, Gisella Di Muzio
N, Mangili P, Del Vecchio A, Fiorino C, Broggi S. Knowledge-based plan
optimization for prostate SBRT delivered with CyberKnife according to RTOG0938
protocol. Phys Med. 2023 Jun;110:102606. doi: 10.1016/j.ejmp.2023.102606. Epub
2023 May 15. PMID: 37196603.
34: Cubero L, García-Elcano L, Mylona E, Boue-Rafle A, Cozzarini C, Ubeira
Gabellini MG, Rancati T, Fiorino C, de Crevoisier R, Acosta O, Pascau J. Deep
learning-based segmentation of prostatic urethra on computed tomography scans
for treatment planning. Phys Imaging Radiat Oncol. 2023 Mar 21;26:100431. doi:
10.1016/j.phro.2023.100431. PMID: 37007914; PMCID: PMC10064422.
35: Cicchetti A, Fiorino C, Ebert MA, Iacovacci J, Kennedy A, Joseph DJ, Denham
JW, Vavassori V, Fellin G, Cozzarini C, Esposti CD, Gabriele P, Munoz F, Avuzzi
B, Valdagni R, Rancati T. Validation of prediction models for radiation-induced
late rectal bleeding: Evidence from a large pooled population of prostate cancer
patients. Radiother Oncol. 2023 Jun;183:109628. doi:
10.1016/j.radonc.2023.109628. Epub 2023 Mar 18. PMID: 36934896.
36: Broggi S, Passoni P, Tiberio P, Cicchetti A, Cattaneo GM, Longobardi B, Mori
M, Reni M, Slim N, Del Vecchio A, Di Muzio NG, Fiorino C. Stomach and duodenum
dose-volume constraints for locally advanced pancreatic cancer patients treated
in 15 fractions in combination with chemotherapy. Front Oncol. 2023 Jan
24;12:983984. doi: 10.3389/fonc.2022.983984. PMID: 36761419; PMCID: PMC9902495.
37: Mori M, Deantoni C, Olivieri M, Spezi E, Chiara A, Baroni S, Picchio M, Del
Vecchio A, Di Muzio NG, Fiorino C, Dell'Oca I. External validation of an
<sup>18</sup>F-FDG-PET radiomic model predicting survival after radiotherapy for
oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1329-1336. doi:
10.1007/s00259-022-06098-9. Epub 2023 Jan 5. PMID: 36604325.
38: Fodor A, Mori M, Tummineri R, Broggi S, Deantoni CL, Mangili P, Baroni S,
Villa SL, Dell'Oca I, Del Vecchio A, Fiorino C, Di Muzio N. CT radiomic
predictors of local relapse after SBRT for lung oligometastases from colorectal
cancer: a single institute pilot study. Strahlenther Onkol. 2023
May;199(5):477-484. doi: 10.1007/s00066-022-02034-w. Epub 2022 Dec 29. PMID:
36580087.
39: Mori M, Palumbo D, Muffatti F, Partelli S, Mushtaq J, Andreasi V, Prato F,
Ubeira MG, Palazzo G, Falconi M, Fiorino C, De Cobelli F. Prediction of the
characteristics of aggressiveness of pancreatic neuroendocrine neoplasms
(PanNENs) based on CT radiomic features. Eur Radiol. 2023 Jun;33(6):4412-4421.
doi: 10.1007/s00330-022-09351-9. Epub 2022 Dec 22. PMID: 36547673.
40: Joseph N, Cicchetti A, McWilliam A, Webb A, Seibold P, Fiorino C, Cozzarini
C, Veldeman L, Bultijnck R, Fonteyne V, Talbot CJ, Symonds PR, Johnson K, Rattay
T, Lambrecht M, Haustermans K, De Meerleer G, Elliott RM, Sperk E, Herskind C,
Veldwijk M, Avuzzi B, Giandini T, Valdagni R, Azria D, Jacquet MF, Charissoux M,
Vega A, Aguado-Barrera ME, Gómez-Caamaño A, Franco P, Garibaldi E, Girelli G,
Iotti C, Vavassori V, Chang-Claude J, West CML, Rancati T, Choudhury A. High
weekly integral dose and larger fraction size increase risk of fatigue and
worsening of functional outcomes following radiotherapy for localized prostate
cancer. Front Oncol. 2022 Oct 26;12:937934. doi: 10.3389/fonc.2022.937934. PMID:
36387203; PMCID: PMC9645430.
41: Dipasquale G, Zilli T, Fiorino C, Achard V, Rouzaud M, Miralbell R. Urinary
toxicity after salvage re-irradiation for prostate cancer local failure after
definitive radiotherapy: a clinical and dosimetric prognostic factors analysis.
J Contemp Brachytherapy. 2022 Jun;14(3):222-226. doi: 10.5114/jcb.2022.117124.
Epub 2022 Jun 14. PMID: 36199992; PMCID: PMC9528846.
42: Fodor A, Brombin C, Mangili P, Fiorino C, Di Muzio N. In Regard to Zureick
et al. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):554-555. doi:
10.1016/j.ijrobp.2022.06.066. PMID: 36152645.
43: Mori M, Palumbo D, De Cobelli F, Fiorino C. Does radiomics play a role in
the diagnosis, staging and re-staging of gastroesophageal junction
adenocarcinoma? Updates Surg. 2023 Feb;75(2):273-279. doi:
10.1007/s13304-022-01377-4. Epub 2022 Sep 17. PMID: 36114920.
44: Shakarami Z, Broggi S, Vecchio AD, Fiorino C, Spinelli AE. Radioluminescence
imaging feasibility for robotic radiosurgery field size quality assurance. Med
Phys. 2022 Oct;49(10):6588-6598. doi: 10.1002/mp.15914. Epub 2022 Aug 24. PMID:
35946490; PMCID: PMC9804764.
45: Cozzarini C, Olivieri M, Magli A, Cante D, Noris Chiorda B, Munoz F, Faiella
A, Olivetta E, Deantoni C, Fodor A, Signor MA, Petrucci E, Avuzzi B, Ferella L,
Pastorino A, Garibaldi E, Gatti M, Rago L, Statuto T, Rancati T, Briganti A,
Montorsi F, Valdagni R, Sanguineti G, Di Muzio NG, Fiorino C. Accurate
prediction of long-term risk of biochemical failure after salvage radiotherapy
including the impact of pelvic node irradiation. Radiother Oncol. 2022
Oct;175:26-32. doi: 10.1016/j.radonc.2022.08.001. Epub 2022 Aug 4. PMID:
35934169.
46: Tudda A, Castriconi R, Benecchi G, Cagni E, Cicchetti A, Dusi F, Esposito
PG, Guernieri M, Ianiro A, Landoni V, Mazzilli A, Moretti E, Oliviero C, Placidi
L, Rambaldi Guidasci G, Rancati T, Scaggion A, Trojani V, Fiorino C. Knowledge-
based multi-institution plan prediction of whole breast irradiation with
tangential fields. Radiother Oncol. 2022 Oct;175:10-16. doi:
10.1016/j.radonc.2022.07.012. Epub 2022 Jul 19. PMID: 35868603.
47: Mori M, Alborghetti L, Palumbo D, Broggi S, Raspanti D, Rovere Querini P,
Del Vecchio A, De Cobelli F, Fiorino C. Atlas-based lung segmentation combined
with automatic densitometry characterization in COVID-19 patients: Training,
validation and first application in a longitudinal study. Phys Med. 2022
Aug;100:142-152. doi: 10.1016/j.ejmp.2022.06.018. Epub 2022 Jul 4. PMID:
35839667; PMCID: PMC9250926.
48: Esposito PG, Castriconi R, Mangili P, Broggi S, Fodor A, Pasetti M, Tudda A,
Di Muzio NG, Del Vecchio A, Fiorino C. Knowledge-based automatic plan
optimization for left-sided whole breast tomotherapy. Phys Imaging Radiat Oncol.
2022 Jun 23;23:54-59. doi: 10.1016/j.phro.2022.06.009. PMID: 35814259; PMCID:
PMC9256826.
49: Cusumano D, Russo L, Gui B, Autorino R, Boldrini L, D'Erme L, Persiani S,
Catucci F, Broggi S, Panza G, Nardangeli A, Campitelli M, Ferrandina G, Macchia
G, Fiorino C, Valentini V, Scambia G, Manfredi R, Gambacorta MA. Evaluation of
early regression index as response predictor in cervical cancer: A retrospective
study on T2 and DWI MR images. Radiother Oncol. 2022 Sep;174:30-36. doi:
10.1016/j.radonc.2022.07.001. Epub 2022 Jul 8. PMID: 35811004.
50: Fiorino C, Rancati T. Artificial intelligence applied to medicine: There is
an "elephant in the room". Phys Med. 2022 Jun;98:8-10. doi:
10.1016/j.ejmp.2022.04.003. Epub 2022 Apr 21. PMID: 35462274.
51: Fodor A, Brombin C, Mangili P, Tummineri R, Pasetti M, Zerbetto F,
Longobardi B, Galvan AS, Deantoni CL, Dell'Oca I, Castriconi R, Esposito PG,
Deli AM, Rancoita PMV, Fiorino C, Vecchio AD, Di Serio MS, Di Muzio NG. Toxicity
of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of
Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients.
Clin Breast Cancer. 2022 Jun;22(4):e480-e487. doi: 10.1016/j.clbc.2021.11.008.
Epub 2021 Dec 1. PMID: 34955430.
52: Pallotta S, Marrazzo L, Calusi S, Castriconi R, Fiorino C, Loi G, Fiandra C.
Implementation of automatic plan optimization in Italy: Status and perspectives.
Phys Med. 2021 Dec;92:86-94. doi: 10.1016/j.ejmp.2021.11.013. Epub 2021 Dec 4.
PMID: 34875426.
53: Di Muzio NG, Deantoni CL, Brombin C, Fiorino C, Cozzarini C, Zerbetto F,
Mangili P, Tummineri R, Dell'Oca I, Broggi S, Pasetti M, Chiara A, Rancoita PMV,
Del Vecchio A, Di Serio MS, Fodor A. Ten Year Results of Extensive Nodal
Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in
Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer. Cancers
(Basel). 2021 Oct 3;13(19):4970. doi: 10.3390/cancers13194970. PMID: 34638454;
PMCID: PMC8508068.
54: Palumbo D, Mori M, Prato F, Crippa S, Belfiori G, Reni M, Mushtaq J, Aleotti
F, Guazzarotti G, Cao R, Steidler S, Tamburrino D, Spezi E, Del Vecchio A,
Cascinu S, Falconi M, Fiorino C, De Cobelli F. Prediction of Early Distant
Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary,
Machine Learning-Based Approach. Cancers (Basel). 2021 Sep 30;13(19):4938. doi:
10.3390/cancers13194938. PMID: 34638421; PMCID: PMC8508250.
55: Castriconi R, Esposito PG, Tudda A, Mangili P, Broggi S, Fodor A, Deantoni
CL, Longobardi B, Pasetti M, Perna L, Del Vecchio A, Di Muzio NG, Fiorino C.
Replacing Manual Planning of Whole Breast Irradiation With Knowledge-Based
Automatic Optimization by Virtual Tangential-Fields Arc Therapy. Front Oncol.
2021 Aug 24;11:712423. doi: 10.3389/fonc.2021.712423. PMID: 34504790; PMCID:
PMC8423088.
56: Fiorino C, Cozzarini C, Fodor A, di Muzio NG. In Regard to Wages et al and
Leite et al. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1548-1549. doi:
10.1016/j.ijrobp.2021.04.045. PMID: 34273332.
57: Placidi L, Castriconi R, Rancati T, Lecchi M, Fusi F, Russo P, Cavedon C,
Fiorino C, Garibaldi C. The scientific publications of AIFM members in
2015-2019: A survey of the FutuRuS working group. Phys Med. 2021 Aug;88:111-116.
doi: 10.1016/j.ejmp.2021.06.011. Epub 2021 Jul 2. PMID: 34225239.
58: Munoz F, Sanguineti G, Bresolin A, Cante D, Vavassori V, Waskiewicz JM,
Girelli G, Avuzzi B, Garibaldi E, Faiella A, Villa E, Magli A, Noris Chiorda B,
Gatti M, Rancati T, Valdagni R, Di Muzio NG, Fiorino C, Cozzarini C. Predictors
of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after
Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers (Basel).
2021 Jun 29;13(13):3243. doi: 10.3390/cancers13133243. PMID: 34209562; PMCID:
PMC8269132.
59: Rancati T, Fiorino C, Sanguineti G, Valdagni R, Orlandi E. Editorial:
Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic
Ratio in the Modern Radiation Therapy Era. Front Oncol. 2021 May 26;11:690649.
doi: 10.3389/fonc.2021.690649. PMID: 34123860; PMCID: PMC8187790.
60: Ebert MA, Gulliford S, Acosta O, de Crevoisier R, McNutt T, Heemsbergen WD,
Witte M, Palma G, Rancati T, Fiorino C. Spatial descriptions of radiotherapy
dose: normal tissue complication models and statistical associations. Phys Med
Biol. 2021 Jun 17;66(12). doi: 10.1088/1361-6560/ac0681. PMID: 34049304.
61: Cusumano D, Boldrini L, Dhont J, Fiorino C, Green O, Güngör G, Jornet N,
Klüter S, Landry G, Mattiucci GC, Placidi L, Reynaert N, Ruggieri R, Tanadini-
Lang S, Thorwarth D, Yadav P, Yang Y, Valentini V, Verellen D, Indovina L.
Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and
physical considerations on state of art and future perspectives. Phys Med. 2021
May;85:175-191. doi: 10.1016/j.ejmp.2021.05.010. Epub 2021 May 19. PMID:
34022660.
62: Mori M, Palumbo D, De Lorenzo R, Broggi S, Compagnone N, Guazzarotti G,
Giorgio Esposito P, Mazzilli A, Steidler S, Pietro Vitali G, Del Vecchio A,
Rovere Querini P, De Cobelli F, Fiorino C. Robust prediction of mortality of
COVID-19 patients based on quantitative, operator-independent, lung CT
densitometry. Phys Med. 2021 May;85:63-71. doi: 10.1016/j.ejmp.2021.04.022. Epub
2021 Apr 30. PMID: 33971530; PMCID: PMC8084622.
63: Bresolin A, Faiella A, Garibaldi E, Munoz F, Cante D, Vavassori V,
Waskiewicz JM, Girelli G, Avuzzi B, Villa E, Magli A, Noris Chiorda B, Gatti M,
Ferella L, Maggio A, Landoni V, Aimonetto S, Sini C, Rancati T, Sanguineti G,
Valdagni R, Di Muzio N, Fiorino C, Cozzarini C. Acute patient-reported
intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume
effect quantification in a multicentric cohort study. Radiother Oncol. 2021
May;158:74-82. doi: 10.1016/j.radonc.2021.02.026. Epub 2021 Feb 25. PMID:
33639190.
64: Benedetti G, Mori M, Panzeri MM, Barbera M, Palumbo D, Sini C, Muffatti F,
Andreasi V, Steidler S, Doglioni C, Partelli S, Manzoni M, Falconi M, Fiorino C,
De Cobelli F. CT-derived radiomic features to discriminate histologic
characteristics of pancreatic neuroendocrine tumors. Radiol Med. 2021
Jun;126(6):745-760. doi: 10.1007/s11547-021-01333-z. Epub 2021 Feb 1. PMID:
33523367.
65: Rossi E, Fiorino C, Fodor A, Deantoni C, Mangili P, Di Muzio NG, Del Vecchio
A, Broggi S. Residual intra-fraction error in robotic spinal stereotactic body
radiotherapy without immobilization devices. Phys Imaging Radiat Oncol. 2020 Oct
3;16:20-25. doi: 10.1016/j.phro.2020.09.006. PMID: 33458339; PMCID: PMC7807594.
66: Fiorino C, Jeraj R, Clark CH, Garibaldi C, Georg D, Muren L, van Elmpt W,
Bortfeld T, Jornet N. In reply to the letter to the editor: "In reply to Fiorino
et al: The central role of the radiation oncologist in the multidisciplinary and
multiprofessional model of modern radiation therapy". Radiother Oncol. 2021
Feb;155:e22-e23. doi: 10.1016/j.radonc.2020.12.033. Epub 2021 Jan 4. PMID:
33412208.
67: Fodor A, Brombin C, Mangili P, Borroni F, Pasetti M, Tummineri R, Zerbetto
F, Longobardi B, Perna L, Dell'Oca I, Deantoni CL, Deli AM, Chiara A, Broggi S,
Castriconi R, Esposito PG, Slim N, Passoni P, Baroni S, Villa SL, Rancoita PMV,
Fiorino C, Del Vecchio A, Bianchini G, Gentilini OD, Di Serio MS, Di Muzio NG.
Impact of molecular subtype on 1325 early-stage breast cancer patients
homogeneously treated with hypofractionated radiotherapy without boost: Should
the indications for radiotherapy be more personalized? Breast. 2021
Feb;55:45-54. doi: 10.1016/j.breast.2020.12.004. Epub 2020 Dec 9. PMID:
33326894; PMCID: PMC7736720.
68: Zuppone S, Bresolin A, Spinelli AE, Fallara G, Lucianò R, Scarfò F, Benigni
F, Di Muzio N, Fiorino C, Briganti A, Salonia A, Montorsi F, Vago R, Cozzarini
C. Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic
Cancers: State-of-the Art and Challenges. Front Oncol. 2020 Oct 22;10:527121.
doi: 10.3389/fonc.2020.527121. PMID: 33194587; PMCID: PMC7642999.
69: Spinelli AE, Bresolin A, Zuppone S, Perani L, Fallara G, Di Muzio N, Vago R,
Fiorino C, Cozzarini C. A non-invasive ultrasound imaging method to measure
acute radiation-induced bladder wall thickening in rats. Radiat Oncol. 2020 Oct
17;15(1):240. doi: 10.1186/s13014-020-01684-3. PMID: 33069240; PMCID:
PMC7568412.
70: Castriconi R, Cattaneo GM, Mangili P, Esposito P, Broggi S, Cozzarini C,
Deantoni C, Fodor A, Di Muzio NG, Vecchio AD, Fiorino C. Clinical Implementation
of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy. Pract
Radiat Oncol. 2021 Mar-Apr;11(2):e236-e244. doi: 10.1016/j.prro.2020.09.012.
Epub 2020 Oct 9. PMID: 33039673.
71: Fiorino C, Jeraj R, Clark CH, Garibaldi C, Georg D, Muren L, van Elmpt W,
Bortfeld T, Jornet N. Grand challenges for medical physics in radiation
oncology. Radiother Oncol. 2020 Dec;153:7-14. doi: 10.1016/j.radonc.2020.10.001.
Epub 2020 Oct 8. PMID: 33039425.
72: Slim N, Passoni P, Incerti E, Tummineri R, Gumina C, Cattaneo GM, De Nardi
P, Canevari C, Fiorino C, Ronzoni M, Tamburini AM, Burgio V, Gianolli L, Di
Muzio N. Impact of sentinel lymph-node biopsy and FDG-PET in staging and
radiation treatment of anal cancer patients. Sci Rep. 2020 Sep 3;10(1):14613.
doi: 10.1038/s41598-020-71577-8. PMID: 32884036; PMCID: PMC7471696.
73: Esposito PG, Castriconi R, Mangili P, Fodor A, Pasetti M, Di Muzio NG, Del
Vecchio A, Fiorino C. Virtual Tangential-fields Arc Therapy (ViTAT) for whole
breast irradiation: Technique optimization and validation. Phys Med. 2020
Sep;77:160-168. doi: 10.1016/j.ejmp.2020.08.011. Epub 2020 Aug 28. PMID:
32866777.
74: Bresolin A, Garibaldi E, Faiella A, Cante D, Vavassori V, Waskiewicz JM,
Girelli G, Avuzzi B, Villa E, Magli A, Noris Chiorda B, Munoz F, Sanguineti G,
Gabriele P, Gatti M, Rancati T, Valdagni R, Di Muzio N, Fiorino C, Cozzarini C.
Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After
Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects.
Front Oncol. 2020 Jul 23;10:1207. doi: 10.3389/fonc.2020.01207. PMID: 32850354;
PMCID: PMC7396712.
75: Cusumano D, Boldrini L, Yadav P, Yu G, Musurunu B, Chiloiro G, Piras A,
Lenkowicz J, Placidi L, Broggi S, Romano A, Mori M, Barbaro B, Azario L,
Gambacorta MA, De Spirito M, Bassetti MF, Yang Y, Fiorino C, Valentini V.
External Validation of Early Regression Index (ERI<sub>TCP</sub>) as Predictor
of Pathologic Complete Response in Rectal Cancer Using Magnetic Resonance-Guided
Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1347-1356.
doi: 10.1016/j.ijrobp.2020.07.2323. Epub 2020 Aug 3. PMID: 32758641.
76: Mori M, Passoni P, Incerti E, Bettinardi V, Broggi S, Reni M, Whybra P,
Spezi E, Vanoli EG, Gianolli L, Picchio M, Di Muzio NG, Fiorino C. Training and
validation of a robust PET radiomic-based index to predict distant-relapse-free-
survival after radio-chemotherapy for locally advanced pancreatic cancer.
Radiother Oncol. 2020 Dec;153:258-264. doi: 10.1016/j.radonc.2020.07.003. Epub
2020 Jul 15. PMID: 32681930.
77: Loi S, Mori M, Benedetti G, Partelli S, Broggi S, Cattaneo GM, Palumbo D,
Muffatti F, Falconi M, De Cobelli F, Fiorino C. Robustness of CT radiomic
features against image discretization and interpolation in characterizing
pancreatic neuroendocrine neoplasms. Phys Med. 2020 Aug;76:125-133. doi:
10.1016/j.ejmp.2020.06.025. Epub 2020 Jul 13. PMID: 32673824.
78: Broggi S, Passoni P, Gumina C, Palmisano A, Bresolin A, Burgio V, Di Chiara
A, Elmore U, Mori M, Slim N, Ronzoni M, Rosati R, De Cobelli F, Di Muzio NG,
Fiorino C. Predicting pathological response after radio-chemotherapy for rectal
cancer: Impact of late oxaliplatin administration. Radiother Oncol. 2020
Aug;149:174-180. doi: 10.1016/j.radonc.2020.05.019. Epub 2020 May 15. PMID:
32417346.
79: Mylona E, Cicchetti A, Rancati T, Palorini F, Fiorino C, Supiot S, Magne N,
Crehange G, Valdagni R, Acosta O, de Crevoisier R. Local dose analysis to
predict acute and late urinary toxicities after prostate cancer radiotherapy:
Assessment of cohort and method effects. Radiother Oncol. 2020 Jun;147:40-49.
doi: 10.1016/j.radonc.2020.02.028. Epub 2020 Mar 28. PMID: 32224316.
80: Fiorino C, Guckemberger M, Schwarz M, van der Heide UA, Heijmen B.
Technology-driven research for radiotherapy innovation. Mol Oncol. 2020
Jul;14(7):1500-1513. doi: 10.1002/1878-0261.12659. Epub 2020 Mar 19. PMID:
32124546; PMCID: PMC7332218.
81: Castriconi R, Fiorino C, Passoni P, Broggi S, Di Muzio NG, Cattaneo GM,
Calandrino R. Knowledge-based automatic optimization of adaptive early-
regression-guided VMAT for rectal cancer. Phys Med. 2020 Feb;70:58-64. doi:
10.1016/j.ejmp.2020.01.016. Epub 2020 Jan 23. PMID: 31982788.
82: Deantoni CL, Fodor A, Cozzarini C, Fiorino C, Brombin C, Di Serio C,
Calandrino R, Di Muzio N. Prostate cancer with low burden skeletal disease at
diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.
Br J Radiol. 2020 Apr;93(1108):20190353. doi: 10.1259/bjr.20190353. Epub 2020
Jan 31. PMID: 31971828; PMCID: PMC7362924.
83: Broggi S, Fiorino C, Chiara A, Salvadori G, Peccatori J, Assanelli A,
Piementose S, Pasetti M, Simone S, Ciceri F, Di Muzio NG, Calandrino R. Clinical
implementation of low-dose total body irradiation using topotherapy technique.
Phys Imaging Radiat Oncol. 2019 Dec 16;12:74-79. doi:
10.1016/j.phro.2019.11.009. PMID: 33458299; PMCID: PMC7807637.
84: Ghadjar P, Fiorino C, Munck Af Rosenschöld P, Pinkawa M, Zilli T, van der
Heide UA. ESTRO ACROP consensus guideline on the use of image guided radiation
therapy for localized prostate cancer. Radiother Oncol. 2019 Dec;141:5-13. doi:
10.1016/j.radonc.2019.08.027. Epub 2019 Oct 23. PMID: 31668515.
85: Mori M, Dell'Oca I, Branchini M, Foti S, Broggi S, Perna L, Cattaneo GM,
Calandrino R, Di Muzio NG, Fiorino C. Monitoring skin dose changes during image-
guided helical tomotherapy for head and neck cancer patients. Strahlenther
Onkol. 2020 Mar;196(3):243-251. English. doi: 10.1007/s00066-019-01520-y. Epub
2019 Oct 4. PMID: 31586231.
86: Incerti E, Vanoli EG, Broggi S, Gumina C, Passoni P, Slim N, Fiorino C, Reni
M, Mapelli P, Cattaneo M, Zanon S, Calandrino R, Gianolli L, Di Muzio N, Picchio
M. Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived
parameters after chemoradiotherapy as predictors of survival in locally advanced
pancreatic carcinoma patients. Nucl Med Commun. 2019 Oct;40(10):1072-1080. doi:
10.1097/MNM.0000000000001065. PMID: 31365502.
87: Fiorino C, Passoni P, Palmisano A, Gumina C, Cattaneo GM, Broggi S, Di
Chiara A, Esposito A, Mori M, Ronzoni M, Rosati R, Slim N, De Cobelli F,
Calandrino R, Di Muzio NG. Accurate outcome prediction after neo-adjuvant radio-
chemotherapy for rectal cancer based on a TCP-based early regression index. Clin
Transl Radiat Oncol. 2019 Jul 3;19:12-16. doi: 10.1016/j.ctro.2019.07.001. PMID:
31334366; PMCID: PMC6617292.
88: Onjukka E, Fiorino C, Cicchetti A, Palorini F, Improta I, Gagliardi G,
Cozzarini C, Degli Esposti C, Gabriele P, Valdagni R, Rancati T. Patterns in
ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta
Oncol. 2019 Dec;58(12):1757-1764. doi: 10.1080/0284186X.2019.1635267. Epub 2019
Jul 12. PMID: 31298076.
89: Fiorino C, Cavedon C, Gori C. On the original article by Ehsan Samei and
Thomas Grist "Why physics in medicine" firstly published on the Journal of
American College of Radiology (2018). Phys Med. 2019 Aug;64:317-318. doi:
10.1016/j.ejmp.2019.04.029. Epub 2019 May 9. PMID: 31080017.
90: Mori M, Benedetti G, Partelli S, Sini C, Andreasi V, Broggi S, Barbera M,
Cattaneo GM, Muffatti F, Panzeri M, Falconi M, Fiorino C, De Cobelli F. Ct
radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust
against delineation uncertainty. Phys Med. 2019 Jan;57:41-46. doi:
10.1016/j.ejmp.2018.12.005. Epub 2018 Dec 18. PMID: 30738530.
91: Cicchetti A, Fiorino C, Rancati T, Valdagni R. In Reply to Loganadane et al.
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):777-778. doi:
10.1016/j.ijrobp.2018.11.001. PMID: 30722974.
92: Branchini M, Broggi S, Dell'Oca I, Cattaneo GM, Calandrino R, Di Muzio NG,
Fiorino C. Skin dose calculation during radiotherapy of head and neck cancer
using deformable image registration of planning and mega-voltage computed
tomography scans. Phys Imaging Radiat Oncol. 2018 Dec 1;8:44-50. doi:
10.1016/j.phro.2018.11.008. PMID: 33458416; PMCID: PMC7807680.
93: Dipasquale G, Zilli T, Fiorino C, Rouzaud M, Miralbell R. Salvage
reirradiation for local failure of prostate cancer after curative radiation
therapy: Association of rectal toxicity with dose distribution and normal-tissue
complication probability models. Adv Radiat Oncol. 2018 Jun 15;3(4):673-681.
doi: 10.1016/j.adro.2018.06.001. PMID: 30370369; PMCID: PMC6200893.
94: Fodor A, Broggi S, Incerti E, Dell'Oca I, Fiorino C, Samanes Gajate AM,
Pasetti M, Cattaneo MG, Passoni P, Gianolli L, Calandrino R, Picchio M, Di Muzio
N. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive
Malignant Pleural Mesothelioma in Patients With Intact Lungs. Clin Lung Cancer.
2019 Jan;20(1):e29-e38. doi: 10.1016/j.cllc.2018.08.019. Epub 2018 Sep 3. PMID:
30253920.
95: Fiorino C, Gumina C, Passoni P, Palmisano A, Broggi S, Cattaneo GM, Di
Chiara A, Esposito A, Mori M, Raso R, Ronzoni M, Rosati R, Slim N, De Cobelli F,
Calandrino R, Di Muzio NG. A TCP-based early regression index predicts the
pathological response in neo-adjuvant radio-chemotherapy of rectal cancer.
Radiother Oncol. 2018 Sep;128(3):564-568. doi: 10.1016/j.radonc.2018.06.019.
Epub 2018 Jun 29. PMID: 30196982.
96: Carrara M, Massari E, Cicchetti A, Giandini T, Avuzzi B, Palorini F, Stucchi
C, Fellin G, Gabriele P, Vavassori V, Degli Esposti C, Cozzarini C, Pignoli E,
Fiorino C, Rancati T, Valdagni R. Development of a Ready-to-Use Graphical Tool
Based on Artificial Neural Network Classification: Application for the
Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1533-1542. doi:
10.1016/j.ijrobp.2018.07.2014. Epub 2018 Aug 6. PMID: 30092335.
97: Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G,
Gabriele P, Vavassori V, Esposti CD, Cozzarini C, Fiorino C, Rancati T, Valdagni
R. Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate
Cancer: New Insights From External Independent Validation. Int J Radiat Oncol
Biol Phys. 2018 Sep 1;102(1):127-136. doi: 10.1016/j.ijrobp.2018.05.013. Epub
2018 Jun 30. PMID: 29970313.
98: Dinapoli N, Barbaro B, Gatta R, Chiloiro G, Casà C, Masciocchi C, Damiani A,
Boldrini L, Gambacorta MA, Dezio M, Mattiucci GC, Balducci M, van Soest J,
Dekker A, Lambin P, Fiorino C, Sini C, De Cobelli F, Di Muzio N, Gumina C,
Passoni P, Manfredi R, Valentini V. Magnetic Resonance, Vendor-independent,
Intensity Histogram Analysis Predicting Pathologic Complete Response After
Radiochemotherapy of Rectal Cancer. Int J Radiat Oncol Biol Phys. 2018 Nov
15;102(4):765-774. doi: 10.1016/j.ijrobp.2018.04.065. Epub 2018 May 4. PMID:
29891200.
99: Belli ML, Mori M, Broggi S, Cattaneo GM, Bettinardi V, Dell'Oca I, Fallanca
F, Passoni P, Vanoli EG, Calandrino R, Di Muzio N, Picchio M, Fiorino C.
Quantifying the robustness of [<sup>18</sup>F]FDG-PET/CT radiomic features with
respect to tumor delineation in head and neck and pancreatic cancer patients.
Phys Med. 2018 May;49:105-111. doi: 10.1016/j.ejmp.2018.05.013. Epub 2018 May
23. PMID: 29866335.
100: Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio
N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T,
Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G,
Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA. More
Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with
Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen
After Surgery: A Long-term, Multi-institutional Analysis. Eur Urol. 2018
Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12. PMID:
29544737.
101: Gigliotti CR, Modorati G, Di Nicola M, Fiorino C, Perna LA, Miserocchi E,
Franzin A, Picozzi P, Bolognesi A, Mortini P, Del Vecchio A, Calandrino R.
Predictors of radio-induced visual impairment after radiosurgery for uveal
melanoma. Br J Ophthalmol. 2018 Jun;102(6):833-839. doi:
10.1136/bjophthalmol-2017-310801. Epub 2017 Sep 13. PMID: 28903963.
102: Rancati T, Palorini F, Cozzarini C, Fiorino C, Valdagni R. Understanding
urinary toxicity after radiotherapy for prostate cancer: first steps forward.
Tumori. 2017 Sep 18;103(5):395-404. doi: 10.5301/tj.5000681. Epub 2017 Sep 7.
PMID: 28885678.
103: Cozzarini C, Rancati T, Palorini F, Avuzzi B, Garibaldi E, Balestrini D,
Cante D, Munoz F, Franco P, Girelli G, Sini C, Vavassori V, Valdagni R, Fiorino
C. Patient-reported urinary incontinence after radiotherapy for prostate cancer:
Quantifying the dose-effect. Radiother Oncol. 2017 Oct;125(1):101-106. doi:
10.1016/j.radonc.2017.07.029. Epub 2017 Aug 18. PMID: 28826629.
104: Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio
N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat
SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V,
Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage
Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-
specific Antigen After Radical Prostatectomy. Eur Urol. 2018 Mar;73(3):436-444.
doi: 10.1016/j.eururo.2017.07.026. Epub 2017 Aug 2. PMID: 28779974.
105: Sini C, Noris Chiorda B, Gabriele P, Sanguineti G, Morlino S, Badenchini F,
Cante D, Carillo V, Gaetano M, Giandini T, Landoni V, Maggio A, Perna L,
Petrucci E, Sacco V, Valdagni R, Rancati T, Fiorino C, Cozzarini C. Patient-
reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy:
First quantification of bowel dose-volume effects. Radiother Oncol. 2017
Aug;124(2):296-301. doi: 10.1016/j.radonc.2017.07.005. Epub 2017 Jul 21. PMID:
28739383.
106: Fiorino C, Broggi S, Di Muzio NG, Fossati N, Briganti A, Cozzarini C.
Salvage radiation therapy after prostatectomy: Understanding the dose-response
effect. Radiother Oncol. 2017 Jun;123(3):486-487. doi:
10.1016/j.radonc.2017.02.020. Epub 2017 May 11. PMID: 28502473.
107: Mapelli P, Broggi S, Incerti E, Alongi P, Kirienko M, Fiorino C, Dell Oca
I, Fallanca F, Vanoli EG, Di Muzio NG, Gianolli L, Picchio M. FDG-PET/CT
Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity
Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
Curr Radiopharm. 2017 Aug 24;10(2):102-110. doi:
10.2174/1874471010666170413151108. PMID: 28412923.
108: Fodor A, Cozzarini C, Fiorino C, Di Muzio NG. In Regard to Pommier et al.
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1109-1110. doi:
10.1016/j.ijrobp.2016.12.026. Epub 2017 Mar 15. PMID: 28333000.
109: Cozzarini C, Benigni F, Fiorino C, Mondino A, Di Muzio N. Reply to Salvador
Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in
the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to
Improve the Therapeutic Ratio of a Potentially Effective but still
Unsatisfactory Treatment? Eur Urol 2017;71:44-5. Preclinical Combinatory
Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested
in the Clinic: Wider Whole-pelvis Radiotherapy Fields and Enhanced Antitumoral
Effect Mediated by T Lymphocytes: A Legitimate Hypothesis? Eur Urol. 2017
Aug;72(2):e34-e35. doi: 10.1016/j.eururo.2017.02.002. Epub 2017 Feb 14. PMID:
28214033.
110: Broggi S, Scalco E, Belli ML, Logghe G, Verellen D, Moriconi S, Chiara A,
Palmisano A, Mellone R, Fiorino C, Rizzo G. A Comparative Evaluation of 3
Different Free-Form Deformable Image Registration and Contour Propagation
Methods for Head and Neck MRI: The Case of Parotid Changes During Radiotherapy.
Technol Cancer Res Treat. 2017 Jun;16(3):373-381. doi: 10.1177/1533034617691408.
Epub 2017 Feb 7. PMID: 28168934; PMCID: PMC5616054.
111: Fodor A, Fiorino C, Picchio M, Di Muzio N. Re: Daniel E. Spratt, Herbert A.
Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-
escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
Eur Urol 2017;71;37-43: High-dose Radiotherapy and Pelvic Lymph Nodal
Irradiation for High-risk Prostate Cancer in the Image-guided Radiotherapy Era.
Eur Urol. 2017 Jun;71(6):e179-e180. doi: 10.1016/j.eururo.2016.12.021. Epub 2017
Jan 5. PMID: 28065538.
112: Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, Briganti A.
Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical
Prostatectomy: Who, When, and How? J Clin Oncol. 2017 Feb;35(4):469-470. doi:
10.1200/JCO.2016.70.2118. Epub 2016 Nov 7. PMID: 28052707.
113: Fiorino C, Gori C. 9th Congress of the Associazione Italiana di Fisica
Medica, Perugia 25-28 February 2016, "Continuity and evolution in medical
physics". Phys Med. 2016 Dec;32(12):1634-1636. doi: 10.1016/j.ejmp.2016.12.009.
PMID: 28024846.
114: Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, Briganti A.
Salvage radiotherapy for patients with rising PSA. Lancet Oncol. 2016
Aug;17(8):e314-e315. doi: 10.1016/S1470-2045(16)30276-5. PMID: 27511150.
115: Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T,
Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F,
Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A.
Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy
Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control
Probability Model. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):333-340. doi:
10.1016/j.ijrobp.2016.06.014. Epub 2016 Jun 18. PMID: 27497691.
116: Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen
T, Cozzarini C, Fiorino C, Noris Chiorda B, Gandaglia G, Dell'Oglio P, Joniau S,
Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal
B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term Impact of Adjuvant
Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated
with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol.
2017 Jun;71(6):886-893. doi: 10.1016/j.eururo.2016.07.028. Epub 2016 Jul 30.
PMID: 27484843.
117: Fiorino C, Cozzarini C, Passoni P. The promise of adaptive radiotherapy for
pelvic tumors: "too high cost for too little result" or "a low cost for a
significant result"? Acta Oncol. 2016 Aug;55(8):939-42. doi:
10.1080/0284186X.2016.1203460. Epub 2016 Jul 1. PMID: 27367444.
118: Cozzarini C, Noris Chiorda B, Sini C, Fiorino C, Briganti A, Montorsi F, Di
Muzio N. Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-
Pelvis Irradiation With Different Intensity Modulated Radiation Therapy
Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a
Longitudinal, Observational Study. Int J Radiat Oncol Biol Phys. 2016 Jun
1;95(2):690-5. doi: 10.1016/j.ijrobp.2016.01.022. Epub 2016 Jan 28. PMID:
27131081.
119: Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, Incerti
E, Dell'Oca I, Cozzarini C, Mangili P, Pasetti M, Calandrino R, Gianolli L, Di
Muzio NG. Toxicity and efficacy of salvage carbon 11-choline positron emission
tomography/computed tomography-guided radiation therapy in patients with lymph
node recurrence of prostate cancer. BJU Int. 2017 Mar;119(3):406-413. doi:
10.1111/bju.13510. Epub 2016 May 24. PMID: 27104782.
120: Fiorino C, Seuntjens J. The role of medical physics in prostate cancer
radiation therapy. Phys Med. 2016 Mar;32(3):435-7. doi:
10.1016/j.ejmp.2016.03.020. Epub 2016 Apr 16. PMID: 27095755.
121: Cozzarini C, Rancati T, Badenchini F, Palorini F, Avuzzi B, Degli Esposti
C, Girelli G, Improta I, Vavassori V, Valdagni R, Fiorino C. Baseline status and
dose to the penile bulb predict impotence 1 year after radiotherapy for prostate
cancer. Strahlenther Onkol. 2016 May;192(5):297-304. English. doi:
10.1007/s00066-016-0964-1. Epub 2016 Apr 14. PMID: 27079673.
122: Landoni V, Fiorino C, Cozzarini C, Sanguineti G, Valdagni R, Rancati T.
Predicting toxicity in radiotherapy for prostate cancer. Phys Med. 2016
Mar;32(3):521-32. doi: 10.1016/j.ejmp.2016.03.003. Epub 2016 Apr 8. PMID:
27068274.
123: Palorini F, Cozzarini C, Gianolini S, Botti A, Carillo V, Iotti C, Rancati
T, Valdagni R, Fiorino C. First application of a pixel-wise analysis on bladder
dose-surface maps in prostate cancer radiotherapy. Radiother Oncol. 2016
Apr;119(1):123-8. doi: 10.1016/j.radonc.2016.02.025. Epub 2016 Mar 15. PMID:
26993415.
124: Fiorino C, Cozzarini C. In Regard to Lewis et al. Int J Radiat Oncol Biol
Phys. 2016 Mar 15;94(4):859-60. doi: 10.1016/j.ijrobp.2016.01.010. PMID:
26972660.
125: Cozzarini C, Briganti A, Fossati N, Montorsi F, Di Muzio N, Fiorino C. Dose
Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to
Pay for a Significant Prospective Benefit. J Clin Oncol. 2016 May
10;34(14):1704-5. doi: 10.1200/JCO.2016.66.7139. Epub 2016 Mar 7. PMID:
26951317.
126: Palorini F, Rancati T, Cozzarini C, Improta I, Carillo V, Avuzzi B,
Casanova Borca V, Botti A, Degli Esposti C, Franco P, Garibaldi E, Girelli G,
Iotti C, Maggio A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Valdagni
R, Fiorino C. Multi-variable models of large International Prostate Symptom
Score worsening at the end of therapy in prostate cancer radiotherapy. Radiother
Oncol. 2016 Jan;118(1):92-8. doi: 10.1016/j.radonc.2015.11.036. Epub 2016 Jan 6.
PMID: 26777123.
127: Belli ML, Broggi S, Scalco E, Cattaneo GM, Dell'Oca I, Logghe G, Moriconi
S, Sanguineti G, Valentini V, Di Muzio N, Fiorino C, Calandrino R. Analysis of
serial CT images for studying the RT effects in head-neck cancer patients. Annu
Int Conf IEEE Eng Med Biol Soc. 2015;2015:5235-8. doi:
10.1109/EMBC.2015.7319572. PMID: 26737472.
128: Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, Sacco
V, Briganti A, Montorsi F, Calandrino R, Di Muzio N, Cozzarini C. Dose-volume
effects for pelvic bone marrow in predicting hematological toxicity in prostate
cancer radiotherapy with pelvic node irradiation. Radiother Oncol. 2016
Jan;118(1):79-84. doi: 10.1016/j.radonc.2015.11.020. Epub 2015 Dec 15. PMID:
26702990.
129: Fiorino C, Muren LP, Clark CH, van Elmpt W, Jornet N. Expanding the
scientific role of medical physics in radiotherapy: Time to act. Radiother
Oncol. 2015 Dec;117(3):401-2. doi: 10.1016/j.radonc.2015.11.007. Epub 2015 Dec
14. PMID: 26700599.
130: Calandrino R, Perna L, Belli ML, Botti A, Cattaneo M, Fiorino C, Cozzarini
C, Iori M. Second Tumor Induction Risk in IMRT for Prostate Cancer: An
Unbalanced Comparison Between Surgery and Radiotherapy? Health Phys. 2015
Dec;109(6):549-55. doi: 10.1097/HP.0000000000000362. PMID: 26509622.
131: Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S,
Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S,
Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the
Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-
specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016
Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21. PMID:
26497924.
132: Incerti E, Fodor A, Mapelli P, Fiorino C, Alongi P, Kirienko M, Giovacchini
G, Busnardo E, Gianolli L, Di Muzio N, Picchio M. Radiation Treatment of Lymph
Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of
Survival Outcomes? J Nucl Med. 2015 Dec;56(12):1836-42. doi:
10.2967/jnumed.115.163741. Epub 2015 Sep 24. PMID: 26405166.
133: Cozzarini C, Rancati T, Carillo V, Civardi F, Garibaldi E, Franco P, Avuzzi
B, Esposti CD, Girelli G, Iotti C, Palorini F, Vavassori V, Valdagni R, Fiorino
C. Multi-variable models predicting specific patient-reported acute urinary
symptoms after radiotherapy for prostate cancer: Results of a cohort study.
Radiother Oncol. 2015 Aug;116(2):185-91. doi: 10.1016/j.radonc.2015.07.048. Epub
2015 Aug 11. PMID: 26276529.
134: Belli ML, Fiorino C, Zerbetto F, Raso R, Broggi S, Chiara A, Cattaneo GM,
Di Muzio N, Dell'oca I, Calandrino R. Early volume variation of positive lymph
nodes assessed by in-room mega voltage CT images predicts risk of loco-regional
relapses in head and neck cancer patients treated with intensity-modulated
radiotherapy. Acta Oncol. 2015;54(9):1490-5. doi: 10.3109/0284186X.2015.1062137.
Epub 2015 Jul 23. PMID: 26203925.
135: Sini C, Broggi S, Fiorino C, Cattaneo GM, Calandrino R. Accuracy of dose
calculation algorithms for static and rotational IMRT of lung cancer: A phantom
study. Phys Med. 2015 Jun;31(4):382-90. doi: 10.1016/j.ejmp.2015.02.013. Epub
2015 Mar 20. PMID: 25801284.
136: Belli ML, Zerbetto F, Raso R, Chiara A, Cattaneo GM, Di Muzio N, Calandrino
R, Fiorino C, Dell'Oca I. Characterization of volume and shape modifications of
PET-positive nodes during Tomotherapy for head and neck cancer as assessed by
MVCTs. Radiother Oncol. 2015 Apr;115(1):50-5. doi: 10.1016/j.radonc.2015.01.020.
Epub 2015 Mar 20. PMID: 25798881.
137: Bortfeld T, Torresin A, Fiorino C, Andreo P, Gagliardi G, Jeraj R, Muren
LP, Paiusco M, Thwaites D, Knöös T. The research versus clinical service role of
medical physics. Radiother Oncol. 2015 Mar;114(3):285-8. doi:
10.1016/j.radonc.2015.02.003. Epub 2015 Feb 26. PMID: 25727681.
138: van der Schaaf A, Langendijk JA, Fiorino C, Rancati T. Embracing
phenomenological approaches to normal tissue complication probability modeling:
a question of method. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):468-71.
doi: 10.1016/j.ijrobp.2014.10.017. Epub 2015 Jan 30. Erratum in: Int J Radiat
Oncol Biol Phys. 2015 Jul 1;92(3):702. doi: 10.1016/j.ijrobp.2015.02.059.. van
der Schaaf, Arjien [corrected to van der Schaaf, Arjen]. PMID: 25680592.
139: Sanguineti G, Ricchetti F, Wu B, McNutt T, Fiorino C. Parotid gland
shrinkage during IMRT predicts the time to Xerostomia resolution. Radiat Oncol.
2015 Jan 17;10:19. doi: 10.1186/s13014-015-0331-x. PMID: 25595326; PMCID:
PMC4307228.
140: Raso R, Scalco E, Fiorino C, Broggi S, Cattaneo GM, Garelli S, Pagliazzi M,
Slim N, di Muzio N, Rizzo G, Calandrino R, Passoni P. Assessment and clinical
validation of margins for adaptive simultaneous integrated boost in neo-adjuvant
radiochemotherapy for rectal cancer. Phys Med. 2015 Mar;31(2):167-72. doi:
10.1016/j.ejmp.2014.12.002. Epub 2015 Jan 10. PMID: 25586933.
141: Fiorino C, Briganti A, Cozzarini C. Re:Mark K. Buyyounouski.
Radiobiological modeling and the study of hypofractionated radiotherapy for
prostate cancer. Eur Urol 2014;66:1031-2. Eur Urol. 2015 Mar;67(3):e56-7. doi:
10.1016/j.eururo.2014.10.032. Epub 2014 Nov 11. PMID: 25466947.
142: Fiorino C, Cozzarini C, Rancati T, Briganti A, Cattaneo GM, Mangili P, Di
Muzio NG, Calandrino R. Modelling the impact of fractionation on late urinary
toxicity after postprostatectomy radiation therapy. Int J Radiat Oncol Biol
Phys. 2014 Dec 1;90(5):1250-7. doi: 10.1016/j.ijrobp.2014.08.347. Epub 2014 Oct
13. PMID: 25442349.
143: Cozzarini C, Fiorino C, Briganti A, Montorsi F, Di Muzio N. Reply to
Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re:
Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected
severe (grade 3-4) late urinary toxicity after postprostatectomy
hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Eur urol 2014;66:1024-30. Eur Urol. 2014 Dec;66(6):e113-4. doi:
10.1016/j.eururo.2014.08.050. Epub 2014 Sep 8. PMID: 25199719.
144: Broggi S, Perna L, Bonsignore F, Rinaldin G, Fiorino C, Chiara A, Frigerio
C, Butti I, Sangalli G, Dell'Oca I, Di Muzio N, Cattaneo GM, Declich F. Static
and rotational intensity modulated techniques for head-neck cancer radiotherapy:
a planning comparison. Phys Med. 2014 Dec;30(8):973-9. doi:
10.1016/j.ejmp.2014.07.001. Epub 2014 Aug 10. PMID: 25113943.
145: Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M,
Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di
Muzio N. Higher-than-expected severe (Grade 3-4) late urinary toxicity after
postprostatectomy hypofractionated radiotherapy: a single-institution analysis
of 1176 patients. Eur Urol. 2014 Dec;66(6):1024-30. doi:
10.1016/j.eururo.2014.06.012. Epub 2014 Jun 27. PMID: 24985964.
146: Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U,
Munoz F, Cosentino D, Cazzaniga LF, Valdagni R, Vavassori V. Daily sodium
butyrate enema for the prevention of radiation proctitis in prostate cancer
patients undergoing radical radiation therapy: results of a multicenter
randomized placebo-controlled dose-finding phase 2 study. Int J Radiat Oncol
Biol Phys. 2014 Jul 1;89(3):518-24. doi: 10.1016/j.ijrobp.2014.03.018. Epub 2014
May 3. PMID: 24803033.
147: Belli ML, Scalco E, Sanguineti G, Fiorino C, Broggi S, Dinapoli N,
Ricchetti F, Valentini V, Rizzo G, Cattaneo GM. Early changes of parotid density
and volume predict modifications at the end of therapy and intensity of acute
xerostomia. Strahlenther Onkol. 2014 Oct;190(11):1001-7. doi:
10.1007/s00066-014-0669-2. Epub 2014 Apr 23. PMID: 24756139.
148: Carillo V, Cozzarini C, Rancati T, Avuzzi B, Botti A, Borca VC, Cattari G,
Civardi F, Esposti CD, Franco P, Girelli G, Maggio A, Muraglia A, Palombarini M,
Pierelli A, Pignoli E, Vavassori V, Zeverino M, Valdagni R, Fiorino C.
Relationships between bladder dose-volume/surface histograms and acute urinary
toxicity after radiotherapy for prostate cancer. Radiother Oncol. 2014
Apr;111(1):100-5. doi: 10.1016/j.radonc.2014.02.006. Epub 2014 Mar 13. PMID:
24631144.
149: Klein EE, Dogan N, Chen Z, Fiorino C. Oncology scan--the vision of medical
physics. Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):251-3. doi:
10.1016/j.ijrobp.2013.08.022. PMID: 24411972.
150: Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M,
Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA,
Menegotti L, Monti AF, Romani F, Stasi M, Valdagni R. Long term rectal function
after high-dose prostatecancer radiotherapy: results from a prospective cohort
study. Radiother Oncol. 2014 Feb;110(2):272-7. doi:
10.1016/j.radonc.2013.09.028. Epub 2013 Dec 11. PMID: 24332020.
151: Scalco E, Fiorino C, Cattaneo GM, Sanguineti G, Rizzo G. Texture analysis
for the assessment of structural changes in parotid glands induced by
radiotherapy. Radiother Oncol. 2013 Dec;109(3):384-7. doi:
10.1016/j.radonc.2013.09.019. Epub 2013 Oct 31. PMID: 24183861.
152: Passoni P, Fiorino C, Slim N, Ronzoni M, Ricci V, Di Palo S, De Nardi P,
Orsenigo E, Tamburini A, De Cobelli F, Losio C, Iacovelli NA, Broggi S,
Staudacher C, Calandrino R, Di Muzio N. Feasibility of an adaptive strategy in
preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy:
boosting the dose to the shrinking tumor. Int J Radiat Oncol Biol Phys. 2013 Sep
1;87(1):67-72. doi: 10.1016/j.ijrobp.2013.05.004. Epub 2013 Jun 19. PMID:
23790770.
153: Sanguineti G, Rao N, Gunn B, Ricchetti F, Fiorino C. Predictors of PEG
dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiother Oncol.
2013 Jun;107(3):300-4. doi: 10.1016/j.radonc.2013.05.021. Epub 2013 Jun 14.
PMID: 23773408.
154: Fellin F, Azzeroni R, Maggio A, Lorentini S, Cozzarini C, Di Muzio N,
Fiorino C, Calandrino R, Schwarz M. Helical tomotherapy and intensity modulated
proton therapy in the treatment of dominant intraprostatic lesion: a treament
planning comparison. Radiother Oncol. 2013 May;107(2):207-12. doi:
10.1016/j.radonc.2013.02.016. Epub 2013 Mar 27. PMID: 23541644.
155: Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio
N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Survival following
biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in
patients with prostate cancer: the impact of competing causes of mortality and
patient stratification. Eur Urol. 2013 Oct;64(4):557-64. doi:
10.1016/j.eururo.2013.03.006. Epub 2013 Mar 13. PMID: 23506833.
156: Maggio A, Carillo V, Cozzarini C, Perna L, Rancati T, Valdagni R, Gabriele
P, Fiorino C. Impact of the radiotherapy technique on the correlation between
dose-volume histograms of the bladder wall defined on MRI imaging and dose-
volume/surface histograms in prostate cancer patients. Phys Med Biol. 2013 Apr
7;58(7):N115-23. doi: 10.1088/0031-9155/58/7/N115. Epub 2013 Mar 11. PMID:
23475338.
157: Carillo V, Cozzarini C, Chietera A, Perna L, Gianolini S, Maggio A, Botti
A, Rancati T, Valdagni R, Fiorino C. Correlation between surrogates of bladder
dosimetry and dose-volume histograms of the bladder wall defined on MRI in
prostate cancer radiotherapy. Radiother Oncol. 2012 Nov;105(2):180-3. doi:
10.1016/j.radonc.2012.10.001. Epub 2012 Nov 22. PMID: 23182056.
158: Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, Sun
M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P,
Montorsi F, Briganti A. Selecting the optimal candidate for adjuvant
radiotherapy after radical prostatectomy for prostate cancer: a long-term
survival analysis. Eur Urol. 2013 Jun;63(6):998-1008. doi:
10.1016/j.eururo.2012.10.036. Epub 2012 Oct 26. PMID: 23122664.
159: Fiorino C, Rizzo G, Scalco E, Broggi S, Belli ML, Dell'Oca I, Dinapoli N,
Ricchetti F, Rodriguez AM, Di Muzio N, Calandrino R, Sanguineti G, Valentini V,
Cattaneo GM. Density variation of parotid glands during IMRT for head-neck
cancer: correlation with treatment and anatomical parameters. Radiother Oncol.
2012 Aug;104(2):224-9. doi: 10.1016/j.radonc.2012.06.003. Epub 2012 Jul 16.
PMID: 22809587.
160: Valdagni R, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna
E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C. Increasing
the risk of late rectal bleeding after high-dose radiotherapy for prostate
cancer: the case of previous abdominal surgery. Results from a prospective
trial. Radiother Oncol. 2012 May;103(2):252-5. doi:
10.1016/j.radonc.2012.03.012. Epub 2012 Apr 20. PMID: 22521747.
161: Maggiulli E, Fiorino C, Passoni P, Broggi S, Gianolini S, Salvetti C, Slim
N, Di Muzio NG, Calandrino R. Characterisation of rectal motion during neo-
adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy:
implications for adaptive dose escalation strategies. Acta Oncol. 2012
Mar;51(3):318-24. doi: 10.3109/0284186X.2012.666358. PMID: 22497434.
162: Carillo V, Cozzarini C, Perna L, Calandra M, Gianolini S, Rancati T,
Spinelli AE, Vavassori V, Villa S, Valdagni R, Fiorino C. Contouring variability
of the penile bulb on CT images: quantitative assessment using a generalized
concordance index. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):841-6. doi:
10.1016/j.ijrobp.2011.12.057. Epub 2012 Mar 6. PMID: 22401919.
163: Ost P, Cozzarini C, De Meerleer G, Fiorino C, De Potter B, Briganti A,
Nagler EV, Montorsi F, Fonteyne V, Di Muzio N. High-dose adjuvant radiotherapy
after radical prostatectomy with or without androgen deprivation therapy. Int J
Radiat Oncol Biol Phys. 2012 Jul 1;83(3):960-5. doi:
10.1016/j.ijrobp.2011.09.007. Epub 2011 Dec 13. PMID: 22172901.
164: Fava G, Widesott L, Fellin F, Amichetti M, Viesi V, Lomax AJ, Lederer L,
Hug EB, Fiorino C, Salvadori G, Di Muzio N, Schwarz M. In-gantry or remote
patient positioning? Monte Carlo simulations for proton therapy centers of
different sizes. Radiother Oncol. 2012 Apr;103(1):18-24. doi:
10.1016/j.radonc.2011.11.004. Epub 2011 Nov 25. PMID: 22119372.
165: Fodor A, Fiorino C, Dell'Oca I, Broggi S, Pasetti M, Cattaneo GM, Gianolli
L, Calandrino R, Di Muzio NG. PET-guided dose escalation tomotherapy in
malignant pleural mesothelioma. Strahlenther Onkol. 2011 Nov;187(11):736-43.
doi: 10.1007/s00066-011-2234-6. Epub 2011 Oct 28. PMID: 22037650.
166: Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V,
Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R. Late
fecal incontinence after high-dose radiotherapy for prostate cancer: better
prediction using longitudinal definitions. Int J Radiat Oncol Biol Phys. 2012
May 1;83(1):38-45. doi: 10.1016/j.ijrobp.2011.06.1953. Epub 2011 Oct 8. PMID:
21985939.
167: Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, Valdagni R,
Vavassori V, Villa S, Fiorino C. Inter-observer variability in contouring the
penile bulb on CT images for prostate cancer treatment planning. Radiat Oncol.
2011 Sep 24;6:123. doi: 10.1186/1748-717X-6-123. PMID: 21943002; PMCID:
PMC3191359.
168: Valdagni R, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, Rancati
T, Avuzzi B, Fiorino C. Long-term biochemical control of prostate cancer after
standard or hyper-fractionation: evidence for different outcomes between low-
intermediate and high risk patients. Radiother Oncol. 2011 Dec;101(3):454-9.
doi: 10.1016/j.radonc.2011.07.017. Epub 2011 Aug 26. PMID: 21872954.
169: Longobardi B, Berardi G, Fiorino C, Alongi F, Cozzarini C, Deli A, La
Macchia M, Perna L, Di Muzio NG, Calandrino R. Anatomical and clinical
predictors of acute bowel toxicity in whole pelvis irradiation for prostate
cancer with Tomotherapy. Radiother Oncol. 2011 Dec;101(3):460-4. doi:
10.1016/j.radonc.2011.07.014. Epub 2011 Aug 22. PMID: 21864924.
170: Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V,
Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R.
Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity
after high dose radiotherapy for prostate cancer. Radiother Oncol. 2011
Jul;100(1):124-30. doi: 10.1016/j.radonc.2011.06.032. Epub 2011 Jul 7. PMID:
21741721.
171: Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E,
Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M,
Giganti MO, Fiorino C. Is it time to tailor the prediction of radio-induced
toxicity in prostate cancer patients? Building the first set of nomograms for
late rectal syndrome. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1957-66.
doi: 10.1016/j.ijrobp.2011.03.028. Epub 2011 Jun 2. PMID: 21640511.
172: Alongi F, Fodor A, Maggio A, Cozzarini C, Fiorino C, Broggi S, Alongi P,
Calandrino R, Muzio ND. Megavoltage CT images of helical tomotherapy unit for
radiation treatment simulation: impact on feasibility of treatment planning in a
prostate cancer patient with bilateral femoral prostheses. Tumori. 2011 Mar-
Apr;97(2):221-4. doi: 10.1177/030089161109700215. PMID: 21617719.
173: Fiorino C, Maggiulli E, Broggi S, Liberini S, Cattaneo GM, Dell'oca I,
Faggiano E, Di Muzio N, Calandrino R, Rizzo G. Introducing the Jacobian-volume-
histogram of deforming organs: application to parotid shrinkage evaluation. Phys
Med Biol. 2011 Jun 7;56(11):3301-12. doi: 10.1088/0031-9155/56/11/008. Epub 2011
May 10. PMID: 21558590.
174: Madaschi S, Fiorino C, Losa M, Lanzi R, Mazza E, Motta M, Perna L, Brioschi
E, Scavini M, Reni M. Time course of hypothalamic-pituitary deficiency in adults
receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother
Oncol. 2011 Apr;99(1):23-8. doi: 10.1016/j.radonc.2011.02.015. Epub 2011 Mar 30.
Erratum in: Radiother Oncol. 2012 Sep;104(3):408. Sara, Madaschi [corrected to
Madaschi, Sara]; Claudio, Fiorino [corrected to Fiorino, Claudio]; Marco, Losa
[corrected to Losa, Marco]; Roberto, Lanzi [corrected to Lanzi, Roberto]; Elena,
Mazza [corrected to Mazza, Elena]; Micaela, Motta [corrected to Mot. PMID:
21458091.
175: Schwarz M, Pierelli A, Fiorino C, Fellin F, Cattaneo GM, Cozzarini C, Di
Muzio N, Calandrino R, Widesott L. Helical tomotherapy and intensity modulated
proton therapy in the treatment of early stage prostate cancer: a treatment
planning comparison. Radiother Oncol. 2011 Jan;98(1):74-80. doi:
10.1016/j.radonc.2010.10.027. Epub 2010 Dec 20. PMID: 21176983.
176: Maggio A, Fiorino C, Mangili P, Cozzarini C, de Cobelli F, Cattaneo GM,
Rancati T, Maschio AD, Muzio ND, Calandrino R. Feasibility of safe ultra-high
(EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by
Helical Tomotheraphy. Acta Oncol. 2011 Jan;50(1):25-34. doi:
10.3109/0284186X.2010.530688. PMID: 21174609.
177: Widesott L, Pierelli A, Fiorino C, Lomax AJ, Amichetti M, Cozzarini C,
Soukup M, Schneider R, Hug E, Di Muzio N, Calandrino R, Schwarz M. Helical
tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation
in high-risk prostate cancer patients: dosimetric, normal tissue complication
probability, and generalized equivalent uniform dose analysis. Int J Radiat
Oncol Biol Phys. 2011 Aug 1;80(5):1589-600. doi: 10.1016/j.ijrobp.2010.10.005.
Epub 2010 Dec 16. PMID: 21167651.
178: Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A,
Briganti A, Broggi S, Deli A, Guazzoni G, Perna L, Pasetti M, Salvadori G,
Montorsi F, Rigatti P, Di Muzio N. Clinical factors predicting late severe
urinary toxicity after postoperative radiotherapy for prostate carcinoma: a
single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys. 2012
Jan 1;82(1):191-9. doi: 10.1016/j.ijrobp.2010.09.027. Epub 2010 Nov 23. PMID:
21109361.
179: Alongi F, Schipani S, Samanes Gajate AM, Rosso A, Cozzarini C, Fiorino C,
Alongi P, Picchio M, Gianolli L, Messa C, Di Muzio N. [11C]choline-PET-guided
helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate
cancer: local control and toxicity profile after 24 months. Tumori. 2010 Jul-
Aug;96(4):613-7. doi: 10.1177/030089161009600416. PMID: 20968143.
180: Sanguineti G, Gunn GB, Parker BC, Endres EJ, Zeng J, Fiorino C. Weekly
dose-volume parameters of mucosa and constrictor muscles predict the use of
percutaneous endoscopic gastrostomy during exclusive intensity-modulated
radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011 Jan
1;79(1):52-9. doi: 10.1016/j.ijrobp.2009.10.057. Epub 2010 Apr 24. PMID:
20418027.
181: Perna L, Alongi F, Fiorino C, Broggi S, Cattaneo Giovanni M, Cozzarini C,
Di Muzio N, Calandrino R. Predictors of acute bowel toxicity in patients treated
with IMRT whole pelvis irradiation after prostatectomy. Radiother Oncol. 2010
Oct;97(1):71-5. doi: 10.1016/j.radonc.2010.02.025. Epub 2010 Mar 20. PMID:
20307910.
182: Motta M, Alongi F, De Martin E, Fiorino C, Maggiulli E, Rigoni L, Landoni
C, Broggi S, Deli AM, Calandrino R, Di Muzio N. Helical tomotherapy for scalp
recurrence of primary eccrine mucinous adenocarcinoma. Tumori. 2009 Nov-
Dec;95(6):832-5. doi: 10.1177/030089160909500632. PMID: 20210254.
183: Broggi S, Fiorino C, Dell'Oca I, Dinapoli N, Paiusco M, Muraglia A,
Maggiulli E, Ricchetti F, Valentini V, Sanguineti G, Cattaneo GM, Di Muzio N,
Calandrino R. A two-variable linear model of parotid shrinkage during IMRT for
head and neck cancer. Radiother Oncol. 2010 Feb;94(2):206-12. doi:
10.1016/j.radonc.2009.12.014. Epub 2010 Feb 1. PMID: 20117852.
184: Faggiano E, Fiorino C, Broggi S, Cattaneo GM, Calandrino R, Cerutti S,
Rizzo G. An automatic deformable registration method to evaluate parotid glands
shrinkage during radiotherapy treatment in Tomotherapy. Annu Int Conf IEEE Eng
Med Biol Soc. 2009;2009:94-7. doi: 10.1109/IEMBS.2009.5334464. PMID: 19964731.
185: Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna
E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Valdagni R. Clinical and
dosimetric predictors of late rectal toxicity after conformal radiation for
localized prostate cancer: results of a large multicenter observational study.
Radiother Oncol. 2009 Nov;93(2):197-202. doi: 10.1016/j.radonc.2009.09.004. Epub
2009 Oct 12. PMID: 19828205.
186: Broggi S, Cozzarini C, Fiorino C, Maggiulli E, Alongi F, Cattaneo GM, Di
Muzio N, Calandrino R. Modeling set-up error by daily MVCT for prostate adjuvant
treatment delivered in 20 fractions: Implications for the assessment of the
optimal correction strategies. Radiother Oncol. 2009 Nov;93(2):246-52. doi:
10.1016/j.radonc.2009.08.029. Epub 2009 Sep 18. PMID: 19766339.
187: Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM,
Calandrino R, Di Muzio N. IMRT significantly reduces acute toxicity of whole-
pelvis irradiation in patients treated with post-operative adjuvant or salvage
radiotherapy after radical prostatectomy. Radiother Oncol. 2009
Nov;93(2):207-12. doi: 10.1016/j.radonc.2009.08.042. Epub 2009 Sep 18. PMID:
19766338.
188: Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for
normal tissues in external radiotherapy: pelvis. Radiother Oncol. 2009
Nov;93(2):153-67. doi: 10.1016/j.radonc.2009.08.004. Epub 2009 Sep 16. PMID:
19765845.
189: Rancati T, Fiorino C, Sanguineti G. NTCP modeling of subacute/late
laryngeal edema scored by fiberoptic examination. Int J Radiat Oncol Biol Phys.
2009 Nov 1;75(3):915-23. doi: 10.1016/j.ijrobp.2009.04.087. Epub 2009 Sep 9.
PMID: 19747783.
190: Cozzarini C, Montorsi F, Fiorino C, Alongi F, Bolognesi A, Da Pozzo LF,
Guazzoni G, Freschi M, Roscigno M, Scattoni V, Rigatti P, Di Muzio N. Need for
high radiation dose (>or=70 gy) in early postoperative irradiation after radical
prostatectomy: a single-institution analysis of 334 high-risk, node-negative
patients. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):966-74. doi:
10.1016/j.ijrobp.2008.12.059. Epub 2009 Jul 18. PMID: 19619960.
191: Valdagni R, Rancati T, Fiorino C. Predictive models of toxicity with
external radiotherapy for prostate cancer: clinical issues. Cancer. 2009 Jul
1;115(13 Suppl):3141-9. doi: 10.1002/cncr.24356. PMID: 19544543.
192: Fiorino C, Rancati T, Valdagni R. Predictive models of toxicity in external
radiotherapy: dosimetric issues. Cancer. 2009 Jul 1;115(13 Suppl):3135-40. doi:
10.1002/cncr.24354. PMID: 19544542.
193: Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio
N, Fazio F, Calandrino R. Dose-volume relationships for acute bowel toxicity in
patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat
Oncol Biol Phys. 2009 Sep 1;75(1):29-35. doi: 10.1016/j.ijrobp.2008.10.086. Epub
2009 May 19. PMID: 19467803.
194: Perna L, Fiorino C, Cozzarini C, Broggi S, Cattaneo GM, De Cobelli F,
Mangili P, Di Muzio N, Calandrino R. Sparing the penile bulb in the radical
irradiation of clinically localised prostate carcinoma: A comparison between MRI
and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy.
Radiother Oncol. 2009 Oct;93(1):57-63. doi: 10.1016/j.radonc.2009.04.004. Epub
2009 May 4. PMID: 19410316.
195: Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G,
Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M. To bleed
or not to bleed. A prediction based on individual gene profiling combined with
dose-volume histogram shapes in prostate cancer patients undergoing three-
dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Aug
1;74(5):1431-40. doi: 10.1016/j.ijrobp.2008.10.021. Epub 2009 Feb 11. PMID:
19211196.
196: Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni
G, Valdagni R, Calandrino R, Fazio F. Phase I-II study of hypofractionated
simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat
Oncol Biol Phys. 2009 Jun 1;74(2):392-8. doi: 10.1016/j.ijrobp.2008.08.038. Epub
2008 Dec 4. PMID: 19056184.
197: Widesott L, Pierelli A, Fiorino C, Dell'oca I, Broggi S, Cattaneo GM, Di
Muzio N, Fazio F, Calandrino R, Schwarz M. Intensity-modulated proton therapy
versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP
evaluation. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):589-96. doi:
10.1016/j.ijrobp.2008.05.065. PMID: 18793962.
198: Begnozzi L, Benassi M, Bertanelli M, Bonini A, Cionini L, Conte L, Fiorino
C, Gabriele P, Gardani G, Giani A, Magri S, Morelli M, Morrica B, Olmi P,
Orecchia R, Penduzzu G, Raffaele L, Rosi A, Tabocchini MA, Valdagni R, Viti V.
Quality assurance of 3D-CRT: indications and difficulties in their applications.
Crit Rev Oncol Hematol. 2009 Apr;70(1):24-38. doi:
10.1016/j.critrevonc.2008.07.016. Epub 2008 Sep 2. PMID: 18768328.
199: Cattaneo GM, Dell'oca I, Broggi S, Fiorino C, Perna L, Pasetti M, Sangalli
G, di Muzio N, Fazio F, Calandrino R. Treatment planning comparison between
conformal radiotherapy and helical tomotherapy in the case of locally advanced-
stage NSCLC. Radiother Oncol. 2008 Sep;88(3):310-8. doi:
10.1016/j.radonc.2008.06.006. Epub 2008 Aug 7. PMID: 18692266.
200: Fiorino C, Alongi F, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N,
Maggiulli E, Mangili P, Perna L, Valdagni R, Fazio F, Calandrino R. Physics
aspects of prostate tomotherapy: planning optimization and image-guidance
issues. Acta Oncol. 2008;47(7):1309-16. doi: 10.1080/02841860802266755. PMID:
18686050.
201: Cozzarini C, Fiorino C, Di Muzio N, Valdagni R, Salonia A, Alongi F, Broggi
S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F. Hypofractionated
adjuvant radiotherapy with helical tomotherapy after radical prostatectomy:
planning data and toxicity results of a Phase I-II study. Radiother Oncol. 2008
Jul;88(1):26-33. doi: 10.1016/j.radonc.2008.03.021. Epub 2008 Apr 30. PMID:
18455253.
202: Iori M, Cattaneo GM, Cagni E, Fiorino C, Borasi G, Riccardo C, Iotti C,
Fazio F, Nahum AE. Dose-volume and biological-model based comparison between
helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother
Oncol. 2008 Jul;88(1):34-45. doi: 10.1016/j.radonc.2008.03.003. Epub 2008 Apr 7.
PMID: 18395811.
203: Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F,
Valdagni R, Fazio F, Calandrino R. Evidence of limited motion of the prostate by
carefully emptying the rectum as assessed by daily MVCT image guidance with
helical tomotherapy. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):611-7. doi:
10.1016/j.ijrobp.2008.01.048. Epub 2008 Apr 18. PMID: 18374511.
204: Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi
C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori
V. Development of a set of nomograms to predict acute lower gastrointestinal
toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008 Jul
15;71(4):1065-73. doi: 10.1016/j.ijrobp.2007.11.037. Epub 2008 Jan 30. PMID:
18234449.
205: De Martin E, Fiorino C, Broggi S, Longobardi B, Pierelli A, Perna L,
Cattaneo GM, Calandrino R. Agreement criteria between expected and measured
field fluences in IMRT of head and neck cancer: the importance and use of the
gamma histograms statistical analysis. Radiother Oncol. 2007 Dec;85(3):399-406.
doi: 10.1016/j.radonc.2007.10.004. Epub 2007 Nov 5. PMID: 17980925.
206: Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, Girelli
G, Mapelli M, Menegotti L, Nava S, Valdagni R. Clinical and dosimetric
predictors of late rectal syndrome after 3D-CRT for localized prostate cancer:
preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol
Phys. 2008 Mar 15;70(4):1130-7. doi: 10.1016/j.ijrobp.2007.07.2354. Epub 2007
Sep 19. PMID: 17881142.
207: Fiorino C, Dell'Oca I, Pierelli A, Broggi S, Cattaneo GM, Chiara A, De
Martin E, Di Muzio N, Fazio F, Calandrino R. Simultaneous integrated boost (SIB)
for nasopharynx cancer with helical tomotherapy. A planning study. Strahlenther
Onkol. 2007 Sep;183(9):497-505. doi: 10.1007/s00066-007-1698-x. PMID: 17762924.
208: Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M,
Montorsi F, Rigatti P, Calandrino R, Fazio F. Significant reduction of acute
toxicity following pelvic irradiation with helical tomotherapy in patients with
localized prostate cancer. Radiother Oncol. 2007 Aug;84(2):164-70. doi:
10.1016/j.radonc.2007.07.013. Epub 2007 Aug 13. PMID: 17706308.
209: Sanguineti G, Adapala P, Endres EJ, Brack C, Fiorino C, Sormani MP, Parker
B. Dosimetric predictors of laryngeal edema. Int J Radiat Oncol Biol Phys. 2007
Jul 1;68(3):741-9. doi: 10.1016/j.ijrobp.2007.01.010. Epub 2007 Mar 29. PMID:
17398024.
210: Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi
C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Valdagni R.
Predictors for rectal and intestinal acute toxicities during prostate cancer
high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol
Biol Phys. 2007 Apr 1;67(5):1401-10. doi: 10.1016/j.ijrobp.2006.10.040. Epub
2007 Jan 22. PMID: 17241754.
211: Roscigno M, Cozzarini C, Scattoni V, Bertini R, Da Pozzo L, Pasta A,
Montorsi F, Bolognesi A, Fiorino C, Colombo R, Fazio F, Rigatti P. A reappraisal
of the role of vesicourethral anastomosis biopsy in patient candidates for
salvage radiation therapy after radical prostatectomy. Radiother Oncol. 2007
Jan;82(1):30-7. doi: 10.1016/j.radonc.2006.11.017. Epub 2006 Dec 21. PMID:
17187884.
212: Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G,
Valdagni R, Gabriele P. Emptying the rectum before treatment delivery limits the
variations of rectal dose - volume parameters during 3DCRT of prostate cancer.
Radiother Oncol. 2006 Sep;80(3):363-70. doi: 10.1016/j.radonc.2006.08.007. Epub
2006 Sep 7. PMID: 16959344.
213: Fiorino C, Dell'Oca I, Pierelli A, Broggi S, De Martin E, Di Muzio N,
Longobardi B, Fazio F, Calandrino R. Significant improvement in normal tissue
sparing and target coverage for head and neck cancer by means of helical
tomotherapy. Radiother Oncol. 2006 Mar;78(3):276-82. doi:
10.1016/j.radonc.2006.02.009. Epub 2006 Mar 20. PMID: 16546279.
214: Longobardi B, De Martin E, Fiorino C, Dell'oca I, Broggi S, Cattaneo GM,
Calandrino R. Comparing 3DCRT and inversely optimized IMRT planning for head and
neck cancer: equivalence between step-and-shoot and sliding window techniques.
Radiother Oncol. 2005 Nov;77(2):148-56. doi: 10.1016/j.radonc.2005.09.011. Epub
2005 Nov 2. PMID: 16260056.
215: Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T,
Fiorino C, Nahum A. Is the alpha-beta ratio of prostate cancer really low? A
prospective, non-randomized trial comparing standard and hyperfractionated
conformal radiation therapy. Radiother Oncol. 2005 Apr;75(1):74-82. doi:
10.1016/j.radonc.2004.12.019. Epub 2005 Apr 18. PMID: 15878104.
216: Fiorino C, Sanguineti G, Valdagni R. Fractionation and late rectal
toxicity: no reliable estimates of alpha/beta value for rectum can be derived
from studies where different volumes of rectum are irradiated at different dose
levels: in regard to Brenner (Int J Radiat Oncol Biol Phys 2004;60:1013-1015.).
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):289-90; author reply 290-1. doi:
10.1016/j.ijrobp.2005.01.015. PMID: 15850935.
217: Fiorino C, Foppiano F, Franzone P, Broggi S, Castellone P, Marcenaro M,
Calandrino R, Sanguineti G. Rectal and bladder motion during conformal
radiotherapy after radical prostatectomy. Radiother Oncol. 2005
Feb;74(2):187-95. doi: 10.1016/j.radonc.2004.10.002. Epub 2004 Oct 28. PMID:
15734207.
218: Sanguineti G, Castellone P, Foppiano F, Franzone P, Marcenaro M, Tognoni P,
Bolognesi A, Ceresoli GL, Fiorino C. Anatomic variations due to radical
prostatectomy. Impact on target volume definition and dose-volume parameters of
rectum and bladder. Strahlenther Onkol. 2004 Sep;180(9):563-72. doi:
10.1007/s00066-004-1245-y. PMID: 15378187.
219: Cozzarini C, Bolognesi A, Ceresoli GL, Fiorino C, Rossa A, Bertini R,
Colombo R, Da Pozzo L, Montorsi F, Roscigno M, Calandrino R, Rigatti P, Villa E.
Role of postoperative radiotherapy after pelvic lymphadenectomy and radical
retropubic prostatectomy: a single institute experience of 415 patients. Int J
Radiat Oncol Biol Phys. 2004 Jul 1;59(3):674-83. doi:
10.1016/j.ijrobp.2003.12.001. PMID: 15183470.
220: Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L,
Piazzolla A, Vavassori V, Valdagni R. Rectal dose-volume constraints in high-
dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys.
2003 Nov 15;57(4):953-62. doi: 10.1016/s0360-3016(03)00665-5. PMID: 14575825.
221: Fiorino C, Gianolini S, Nahum AE. A cylindrical model of the rectum:
comparing dose-volume, dose-surface and dose-wall histograms in the radiotherapy
of prostate cancer. Phys Med Biol. 2003 Aug 21;48(16):2603-16. doi:
10.1088/0031-9155/48/16/303. PMID: 12974577.
222: Foppiano F, Fiorino C, Frezza G, Greco C, Valdagni R; AIRO National Working
Group on Prostate Radiotherapy. The impact of contouring uncertainty on rectal
3D dose-volume data: results of a dummy run in a multicenter trial
(AIROPROS01-02). Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):573-9. doi:
10.1016/s0360-3016(03)00659-x. PMID: 12957271.
223: Corletto D, Iori M, Paiusco M, Brait L, Broggi S, Ceresoli G, Iotti C,
Calandrino R, Fiorino C. Inverse and forward optimization of one- and two-
dimensional intensity-modulated radiation therapy-based treatment of concave-
shaped planning target volumes: the case of prostate cancer. Radiother Oncol.
2003 Feb;66(2):185-95. doi: 10.1016/s0167-8140(02)00375-4. PMID: 12648791.
224: Cozzarini C, Fiorino C, Ceresoli GL, Cattaneo GM, Bolognesi A, Calandrino
R, Villa E. Significant correlation between rectal DVH and late bleeding in
patients treated after radical prostatectomy with conformal or conventional
radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys. 2003 Mar
1;55(3):688-94. doi: 10.1016/s0360-3016(02)04117-2. PMID: 12573756.
225: Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM,
Foppiano F, Magli A, Piazzolla A. Relationships between DVHs and late rectal
bleeding after radiotherapy for prostate cancer: analysis of a large group of
patients pooled from three institutions. Radiother Oncol. 2002 Jul;64(1):1-12.
doi: 10.1016/s0167-8140(02)00147-0. PMID: 12208568.
226: Fiorino C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM, Piazzolla A,
Cozzarini C. Rectum contouring variability in patients treated for prostate
cancer: impact on rectum dose-volume histograms and normal tissue complication
probability. Radiother Oncol. 2002 Jun;63(3):249-55. doi:
10.1016/s0167-8140(01)00469-8. PMID: 12142088.
227: Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R,
Villa E, Lambertenghi-Deliliers G, Fiorino C. Lethal pulmonary complications
significantly correlate with individually assessed mean lung dose in patients
with hematologic malignancies treated with total body irradiation. Int J Radiat
Oncol Biol Phys. 2002 Feb 1;52(2):483-8. doi: 10.1016/s0360-3016(01)02589-5.
PMID: 11872296.